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ABSTRACT OF THE DISSERTATION
Role of Slit2 in Reducing Complications After Surgical Brain Injury
by
Prativa Sherchan
Doctor of Philosophy, Graduate Program in Physiology
Loma Linda University, March 2016
Dr. John H. Zhang, Chairperson

Surgical brain injury (SBI) is the inadvertent injury to brain tissue at the
perisurgical site which occurs due to neurosurgical maneuvers such as incision,
retraction, and electrocoagulation that can result in post-operative complications.
Blood brain barrier (BBB) disruption and neuroinflammation are major
pathophysiological consequences after neurosurgical injury. Blood brain barrier
dysfunction leads to increased influx of water and plasma proteins as well as
peripheral immune cell infiltration into the brain parenchyma that further
potentiates brain edema and worsens post-operative neurological function.
Activated resident immune cells and infiltrated peripheral immune cells release
inflammatory mediators and promote oxidative stress and cell death which
contributes to neuroinflammation and progression of injury.
In this project we have identified Slit2, an extracellular matrix protein
expressed endogenously in the brain, as a potential therapeutic target for
reducing SBI-induced complications. Our central hypothesis was that Slit2 will
increase after SBI as an endogenous protective mechanism, and recombinant
Slit2 pretreatment will reduce neuroinflammation and stabilize the BBB via Robo
receptor signaling pathway. The dual effects of Slit2— anti-migratory and anti-
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permeability—were explored under three aims using the rat SBI model. The first
aim evaluated the role of Slit2 in reducing neuroinflammation and BBB
permeability after SBI. The second aim investigated the role of Slit2 and its
receptor Robo1 in reducing neuroinflammation after SBI. Lastly, the third aim
investigated the role of Slit2 and its receptor Robo4 in stabilizing the BBB after
SBI.
Our findings showed that endogenous Slit2 increased in the perisurgical
site in response to injury and had a protective function after SBI. Exogenous
recombinant Slit2 pretreatment attenuated brain edema and neuroinflammation
and thereby improved neurological function after SBI. Furthermore, we observed
that recombinant Slit2 reduced neuroinflammation after SBI by inhibiting
peripheral immune cell infiltration to the injury site possibly through Robo1srGAP1 pathway mediated Cdc42 inactivation. Lastly, we elucidated that
recombinant Slit2 reduced BBB permeability by stabilizing endothelial tight
junction after experimental SBI possibly via Robo4-paxillin dependent Rac1
activation.
These observations suggest that Slit2 may be beneficial to reduce
neurosurgical injury and improve post-operative outcomes in neurosurgical
patients.
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CHAPTER ONE
INTRODUCTION TO SURGICAL BRAIN INJURY

Adapted from

Sherchan P., Kim C. H., Zhang J. H. (2013). Surgical Brain Injury and Edema
Prevention. In Brain Edema XV, Acta Neurochirurgica Supplement, 118:
129-133. New York, NY: Springer Science.
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Surgical Brain Injury
Surgical brain injury (SBI) is the inadvertent injury to brain tissue at the
perisurgical site which occurs due to neurosurgical maneuvers (Jadhav et al.,
2007a, Huang et al., 2014). The unique nature of brain tissue poses considerable
challenges for neurosurgery. Under the rigid and tough protection of the skull and
meninges, the brain is extremely vulnerable to the mechanical insults produced
by neurosurgical maneuvers, such as direct incisions, electrocauterization, and
retraction. Healthy tissues at the margins of the operative target are inevitably
subjected to injury during surgical procedures.
Post-operative complications are frequently encountered after intracranial
surgeries, which increase patient morbidity and mortality (Bruder and Ravussin,
1999, Rolston et al., 2014). Major complications are encountered in 13-27%
patients after intracranial surgeries (Bruder, 2002). New onset of neurological
deficits or worsening of neurological function is reported to be the second most
common adverse event encountered after intracranial surgeries with a reported
occurrence of up to 20% (Wong et al., 2012). Blood brain barrier (BBB)
disruption, hemorrhage and neuroinflammation are major pathophysiological
consequences of SBI that can result in post-operative complications such as
brain edema and neurological deficits following neurosurgeries (Bruder, 2002,
Yamaguchi et al., 2007, Hyong et al., 2008)

2

Pathophysiology of Surgical Brain Injury
Brain Edema
Post-operative edema has been reported to occur in 2 to 10% cases
following neurosurgical procedures in a literature review series that examined the
frequency of occurrence of adverse events after cranial tumor resection (Wong et
al., 2012). The blood brain barrier comprising the vascular endothelium, pericyte,
and astrocytic processes, prevents the leakage of plasma proteins from the
vascular bed into the brain tissue (Nag et al., 2009). Vasogenic edema results
from the passage of water along with plasma proteins into the brain tissue
because of damage to the capillary endothelium and the interendothelial tight
junctions of the BBB, whereas cellular swelling of the injured brain cells results in
cytotoxic edema (Nag et al., 2011). Both result in increased intracranial pressure,
which may lead to further brain injury from cell death or hypoperfusion (Bruder
and Ravussin, 1999).

Neuroinflammation
Neuroinflammation plays an important role in the progression of brain
edema after neurosurgical injury (Hyong et al., 2008). Previous studies have
shown evidence of neuroinflammation characterized by increase in
proinflammatory cytokines, proinflammatory enzymes, activation of resident
immune cells and infiltration of peripheral leukocytes at the perisurgical site
(Hyong et al., 2008, Ayer et al., 2012, Huang et al., 2015). Activated resident
immune cells and infiltrated peripheral immune cells release inflammatory
mediators and promote oxidative stress and cell death which contributes to
3

progression of the injury (Petty and Lo, 2002, Yilmaz et al., 2006, Lo, 2009).
Recent studies show that targeting specific inflammatory insult reduced
perisurgical brain edema and improved outcomes after experimental SBI (Huang
et al., 2015, Sherchan et al., 2015).

Surgical Brain Injury Rat Model
Currently, SBI is clinically addressed by nonspecific postoperative care;
however, it has become possible to study potential therapies in the preclinical
laboratory setting using the rodent model for SBI. The SBI rat model was
designed to mimic injuries sustained from neurosurgical manipulation of brain
tissue. The rodent brain is exposed through a small cranial window in the right
frontal bone through which partial frontal lobe resection is performed. The
margins of the resection are designated in relation to the bregma, as shown in
Fig. 1.

4

Figure 1. Partial right frontal lobe resection. Two incisions (dashed lines) are made
leading away from the bregma (white X) along the sagittal and coronal planes, 2
mm lateral to sagittal and 1 mm rostral to coronal respectively.

5

The SBI model provides consistently measureable brain edema using the
brain water content in the perisurgical site. Studies have shown that brain edema
in the perisurgical site peaked 24 h after inducing SBI, was significantly higher up
to day 3 post-injury, and subsided by day 7; SBI was associated with
neurobehavior deficits that dissipated by day 7 (Matchett et al., 2006, Jadhav et
al., 2007b, Yamaguchi et al., 2007). The SBI rat model allows opportunity to
better understand SBI pathophysiology and to test specific SBI targeted
therapeutic strategies for possible clinical use in neurosurgical patients. The
experimental therapeutics that have been tested in the SBI rodent model is
outlined in Table 1 and has been further discussed in this chapter.
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Table 1. Experimental rodent studies of therapeutic agents for surgical brain
injury.
References
Matchett et al., J
Neurosci.Methods, 2006
Lo et al., Neurosci Lett,
2007
Jadhav et al., J
Neurosurg, 2007
Yamaguchi et al.,
Neurosurgery, 2007
Lee et al., Acta
Neurochir Suppl,2008

Treatment
Erythropoietin
pretreatment
NADPH oxidase
KO or apocynin
pretreatment
PP1 pretreatment
MMP inhibitor-1
pretreatment
Simvastatin
Pretreatment

SBI findings
Treatment outcomes
SBI: brain water content (BWC)
Treatment (Tx): harmful, BWC
SBI: BWC, neurological scores (NS)
KO: NS
Tx: no effect
SBI: VEGF, p-ERK1/2, ZO-1,BWC
Tx: VEGF, p-ERK1/2, ZO-1, BWC
SBI: BWC, NS
Tx: BWC
SBI: BWC, NS
Tx: no effect
SBI: BWC, NS, lipid peroxidation
(LPO)
Tx (low dose): BWC, NS, LPO
Tx (high dose): BWC, NS, LPO

Lee et al., Acta
Neurochir Suppl, 2008

Melatonin
pretreatment

Bravo et al., Brain Res,
2008

L-histidine and
thioperamide
post-treatment

SBI: BWC, NS
Tx: BWC

Hyong et al., Brain Res,
2008

Rosiglitazone
pretreatment

SBI: BWC, NS, myeloperoxidase
(MPO), TNF, IL-1
Tx: MPO, TNF, IL-1

Di et al., Neurosci Lett,
2008
Hao et al., Brain Res
2009

Aminoguanidine
post-treatment

Jadhav et al., Stoke,
2009

Hyperbaric
oxygen
preconditioning
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SBI: BWC, NS, TNF, NF-
SBI: malondialdehyde (MDA),
glutathione (GSH), aquaporin-4 (AQ-4)
Tx: BWC, MDA, GSH, AQ-4
SBI: BWC, NS, cyclooxygenase-2
(COX-2), hypoxia inducible factor-1
(HIF-1)
Tx: BWC, NS, COX-2, HIF-1

Experimental Therapeutics for Surgical Brain Injury
Vascular Endothelial Growth Factors
Vascular endothelial growth factors (VEGFs) are a large family of proteins
designated VEGF-A through VEGF-E and are expressed in the choroid plexus
and neurons in the normal brain (Merrill and Oldfield, 2005). A well-known growth
factor with angiogenic, mitogenic, and permeability-inducing effects, VEGF has
also been shown to contribute to SBI-induced brain edema. VEGF-A has a
potent hyperpermeability inducing effect on the microvascular endothelium that is
mediated through its receptor VEGF receptor-2 (VEGF-2, kdr) (Merrill and
Oldfield, 2005). VEGF-2, a transmembrane tyrosine kinase present in the
endothelium of the brain vessels, activates MAPK signaling (Kusaka et al., 2004).
An upregulation in VEGF has also been reported in models of TBI predominantly
due to the infiltrating neutrophils (Chodobski et al., 2003). VEGF administration
and overexpression with viral vectors have both been associated with
compromised integrity of the BBB in the rodent brain (Proescholdt et al., 1999). A
potential mechanism by which VEGF-A might increase BBB permeability involves
downregulating the expression of occludin, a tight junction protein; this would
disrupt the organization of occludin and ZO-1, another junctional protein, leading
to tight junction disassembly (Petty and Lo, 2002). Although VEGF may have
potentially reparative actions during later phases after an injury, early inhibition of
VEGF or its upstream mediator Src tyrosine kinase have been shown to reduce
brain edema in various stroke models (Kusaka et al., 2004, Jadhav et al., 2007a).
The expression of VEGF was increased at 24 h after SBI in the ipsilateral frontal
region surrounding the surgical resection site (Jadhav et al., 2007b). The Src
8

family is implicated in VEGF-dependent hyperpermeability and has been shown
to be involved in SBI-induced BBB disruption and subsequent brain edema in
rodents (Jadhav et al., 2007b). An increase in expression of VEGF and p-ERK
1/2 as well as a corresponding decrease in the tight junction protein ZO-1 were
reversed when rats were pretreated with PP1, an Src tyrosine kinase inhibitor,
prior to inducing SBI (Jadhav et al., 2007b). In addition, VEGF was shown to play
a possible role in the erythropoietin-induced increase in brain edema during the
early phase in a SBI rodent model. Erythropoietin administration led to
significantly increased brain water content in the perisurgical region at 24 h and
was associated with increased expression of VEGF (Matchett et al., 2006). Thus,
VEGF-A and its upstream Src tyrosine kinase present potential therapeutic
targets for preserving the BBB and reducing brain edema following neurosurgical
procedures.
VEGF-B, another member of the VEGF family expressed in the CNS,
mediates its effects through the VEGF receptor-1 (VEGF-1, flt-1); VEGF-B is
likely responsible for maintaining the BBB in a steady state. Furthermore, when
bound to the soluble extracellular portion of VEGFR- 1, VEGF is inactive,
sequestered, and unable to bind to VEGF receptors. The role of VEGF-B and its
receptors in brain edema development following SBI remains to be elucidated
(Merrill and Oldfield, 2005).

Matrix Metalloproteinases
Matrix metalloproteinases (MMPs), zinc-dependent endopeptidases

9

involved in tissue remodeling and repair, have been implicated in the SBIinduced destruction of the extracellular matrix proteins of the neurovascular unit.
The target substrates of MMPs include collagen IV, fibronectin, and laminin, all of
which are critical to maintaining the integrity of the BBB. MMP-2 (gelatinase A)
and MMP-9 (gelatinase B) degrade the basal lamina and tight junction proteins of
the BBB and promote BBB injury that leads to vasogenic edema during the acute
stage in experimental models of brain injury and stroke (Petty and Lo, 2002,
Donkin and Vink, 2010). Upregulation of MMPs has been demonstrated following
subarachnoid hemorrhage, cerebral ischemia, traumatic brain injury (TBI), and
intracerebral hemorrhage, and has been shown to contribute to BBB disruption
during the early stage of injury (Sehba et al., 2004, Rosenberg and Yang, 2007,
Ding et al., 2009, Wu et al., 2010). Additionally, MMP-9 knockout mice had
improved functional outcomes, lowered BBB permeability, and reduced lesion
volume after transient focal cerebral ischemia and TBI (Wang et al., 2000, Asahi
et al., 2001). Similarly, the role of MMPs in mediating BBB disruption and brain
edema after SBI was demonstrated by Yamaguchi and colleagues. An
upregulation of MMP-2 and MMP-9 was temporally associated with BBB
disruption after SBI in rats. A significant increase in MMP activity, particularly that
of MMP-9, compared with pre-surgery levels was detected at days 1–14 after
SBI, with highest MMP activities observed at days 1 and 3 coinciding with peak
values in brain edema; MMP inhibitor, reversed these effects, preserving the
BBB integrity and reducing SBI-induced brain edema as early as 3 h post-injury
(Yamaguchi et al., 2007). Evidence of the role of MMPs in the development of
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brain edema in the early stages after stroke and in SBI models supports the
potential use of MMP inhibition to prevent brain edema following neurosurgical
procedures.

Cyclooxygenase-2
Various inflammatory mediators have been implicated in BBB disruption
and brain edema after stroke and brain injury. The role of cyclooxygenases,
enzymes that catalyze the conversion of arachidonic acid to prostaglandins and
thromboxanes, in mediating brain edema development has been extensively
studied. The upregulation of cyclooxygenase-2 (COX-2), expressed in various
cell types including neurons, astrocytes, endothelial cells, macrophages, and
microglia in the CNS, has been demonstrated following focal and global cerebral
ischemia, neonatal hypoxia–ischemia, and intracerebral hemorrhage (Chu et al.,
2004, Donkin and Vink, 2010, Fathali et al., 2010, Cheng et al., 2011). Selective
inhibition of COX-2 provided protection after ICH by reducing prostaglandin E

2

production, thereby decreasing inflammation, brain edema, and cell death, which
translated into improved functional recovery (Chu et al., 2004). Further, the role
of COX-2 in mediating ischemic preconditioning-induced protection has been
suggested. COX-2 has been shown to mediate ischemic preconditioning in vitro
(Kim et al., 2007). Studies from our laboratory have determined COX-2 to be a
potential mediator of hyperbaric oxygen preconditioning (HBO-PC) in SBI and
global ischemia rodent models; animals preconditioned for 1 h daily for 5 days
with HBO prior to inducing injury had significantly improved neurological function
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and brain edema (Jadhav et al., 2009, Cheng et al., 2011). Cyclooxygenase-2
has been shown to play a part in SBI pathophysiology as well. An increase in
COX-2 expression was detected 24 h after SBI in mice, and HBO-PC
significantly attenuated the increase in COX-2 possibly through suppression of
HIF-1, the upstream regulator of COX-2 (Ostrowski et al., 2005). The study
showed that HBO-PC increased COX-2 level two-fold in comparison to the
fourfold increase by the SBI, which suggested that protection conferred by HBOPC might have involved brain preconditioning by increasing COX-2 to sub
injurious levels. Furthermore, the protective effects of HBO-PC were reversed in
the presence of selective COX-2 inhibitor. These studies demonstrate HBO-PC
or COX-2 inhibition to be promising therapies in attenuating brain edema
following neurosurgical procedures.

Conclusion
The SBI rodent model mimics injuries caused by neurosurgical procedures
and produces post-operative brain edema. It allows for the study of the cellular
signaling pathways and the identification of key molecular targets for
neuroprotective pretreatment before neurosurgical intervention. The various
edema promoting factors including VEGF, MMPs, and COXs have been revealed
to be potential targets for therapy. Similarly, recent studies have explored specific
neuroinflammatory therapies to target SBI induced complications.
As clinically applicable therapeutic intervention for SBI is likely to result in
significant benefits for patients and healthcare organizations, further preclinical
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and clinical studies are necessary to explore the applicability of these targets.
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CHAPTER TWO
ROLE OF SLIT2 IN CNS PATHOLOGY

Introduction to Slit2-Robo
Slits are evolutionarily conserved extracellular matrix proteins originally
identified in the nervous system (Ballard and Hinck, 2012, Yuen and Robinson,
2013). Slit proteins are key regulators in guiding the migration of axons and
neuronal precursors during development by preventing abnormal midline
crossings (Marillat et al., 2002). The mammalian Slit protein contains an Nterminal signal peptide, four leucine-rich repeats (LRRs), nine epidermal growth
factor repeats (EGF), a laminin G domain, and a cysteine rich C terminus (Wong
et al., 2002). There are three known isoforms of Slit (Slit1-Slit3) in the vertebrates
(Wong et al., 2002, Chaturvedi and Robinson, 2015). Slit1 is predominantly
expressed in the developing nervous system but Slit2 and Slit3 are also
expressed outside the nervous system including the kidney, lung, heart and
immune cells (Wu et al., 2001, Prasad et al., 2007, Chaturvedi and Robinson,
2015). Among the Slit proteins, Slit2 has been most widely studied during
pathological states in the nervous system. Slit2 is expressed by neurons in the
normal adult brain (Marillat et al., 2002, Guan and Rao, 2003). However, in
response to injury Slit2 is expressed by glial cells in addition to the neurons
(Hagino et al., 2003), which implicates distinct function of Slit2 in the adult brain
after an injury.
Slit2 exerts its function by binding to its receptor Roundabout (Robo)
(Guan and Rao, 2003). The Robo family of transmembrane receptors (Robo118

Robo4) mediates the intracellular signal transduction pathways for the Slit
ligands. Robo is a single-pass transmembrane protein which belongs to the
immunoglobulin superfamily (Ballard and Hinck, 2012). The extracellular region
of Robo contains five immunoglobulin (Ig) domains and three fibronectin type III
repeats, a transmembrane domain and four conserved cytoplasmic motifs (CC0CC3) (Guan and Rao, 2003). The LRR domain of Slit2 directly binds with the Ig
domain of Robo to transduce downstream signaling pathways (Ballard and
Hinck, 2012). Among the Robo family, the Robo1 receptor is expressed by
neurons in the normal brain while glial cells are either negative or faintly positive
for Robo1 expression (Mertsch et al., 2008) whereas, Robo4 is expressed by the
brain microvascular endothelial cells (Cai et al., 2015). In addition, Robo1 is also
highly expressed by non-neuronal cells such at the peripheral immune cells (Wu
et al., 2001, Prasad et al., 2007)

Role of Slit2 During CNS Development
Multiple factors are involved in guiding the axons projecting from diverse
neuronal populations in the brain towards the appropriate direction (Zhang et
al., 2012). Among such factors, Slit2-Robo signaling has emerged as a
conserved system that guides the path of axons in the developing nervous
system across species. Slit proteins in the brain are crucial during development
of the forebrain axons since it maintains the proper position, extension and
crossing of axons and axonal tracts in the forebrain (Nguyen-Ba-Charvet and
Chedotal, 2002). During development the forebrain exhibits complementary
pattern of expression of the Slit proteins (1 and 2) and Robo (1 and 2). The
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projecting axons avoid regions expressing high levels of Slit2 mRNA during
development of the axonal tract projections in embryonic mice (Nguyen-BaCharvet and Chedotal, 2002). Additionally, Slit mutant mice exhibited abnormal
patterns and positioning of axonal tract projections during development
(Nguyen-Ba-Charvet and Chedotal, 2002). There is some evidence that in
addition to Slit2, the other Slits also aid in the guidance of the developing
axons. Slit2 antisense morpholino oligoneucleotides that targeted translation of
Slit2 mRNA reduced the formation of axonal projections, and simultaneous
inhibition of both Slit2 and Slit3 function further reduced the projecting axons
(Zhang et al., 2012). Additionally, Robo2 knockdown led to severe loss of the
forebrain descending tract fibers (Alajez et al., 2011). Likewise, studies using
Slit or Robo knockout mice showed that axons abnormally approached and
crossed the midline during development in different regions of the brain (Bagri
et al., 2002, Andrews et al., 2006, Lopez-Bendito et al., 2007, Zhang et al.,
2012).
Although initially identified as an axonal repellent critical for development
of the nervous system, the function of Slit2-Robo has been expanded to regulate
disease processes in the CNS, which is discussed further in this chapter.

Role of Slit2 in CNS Disorders
Glioma
Malignant glioma is the most common primary brain tumor in adults and is
associated with high mortality and poor prognosis. (Gu et al., 2015). The invasive
nature of glioma increases the risk of its recurrence despite surgical removal and
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is the most common indicator for poor prognosis (Gu et al., 2015). The
dysregulation of cell motility has been postulated to be involved in promoting
glioma cell infiltration which might promote the invasive nature of the tumor (Yiin
et al., 2009, Gu et al., 2015).
While the role of Slit-Robo system in axon and neuronal migration is well
established, its role in CNS tumors has remained relatively unexplored. Slit2 is
normally expressed by neurons and astrocytes in the normal brain and is
reported to have a tumor suppressive function (Mertsch et al., 2008, Xu et al.,
2010) In human glioma cells Slit2 was expressed at very low levels (Mertsch et
al., 2008, Yiin et al., 2009) and more so with malignant progression (Mertsch et
al., 2008). However, the percent of tumors that expressed Robo1 increased as
the invasiveness of the tumor progressed (Mertsch et al., 2008). Mertsch et al.
suggested that hypermethylation of the SLIT2 promoter associated with
increasing grade of glioma may be responsible for the lower expression of Slit2 in
high grades tumors similar to what has reported in peripheral tumors outside the
CNS including colorectal, lung, renal, breast and cervical cancers (Mertsch et al.,
2008). There is some supporting evidence that methylation of SLIT2 gene
regulates its expression in glioma cells. While normal brain samples lacked any
methylation at the SLIT2 promoter region, the CpG island on the SLIT2 promoter
was frequently hypermethylated in tumor samples (59%) and in glioma cell lines
(71%) with a corresponding loss in the expression of Slit2, which was restored
after treatment with demethylating agent 5-aza-2'-deoxycytidine (Dallol et al.,
2003). This was associated with reduced expression of Slit2 depending on the
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degree of methylation of the promoter. Furthermore, treatment with
demethylating agent restored SLIT2 gene expression in the methylated glioma
cell lines but did not change the expression of SLIT2 in unmethylated glioma cell
lines indicating that the hypermethylation of SLIT2 promoter resulted in reduced
expression of Slit2 in the tumors (Dallol et al., 2003)
Even though the Slit-Robo system has been shown to be important
regulators in the guiding the motility of various cell types, fewer studies have
examined the involvement of Slit2 and Robo in tumor cell migration in the CNS.
Yinn et al. observed that glioma cells treated with recombinant Slit2 or stably
transfected with Slit2 gene exhibited reduced capacity to migrate and invade
compared to controls in vitro (Yiin et al., 2009). In addition, when glioma cells
transfected with Slit2 gene were implanted intracranially, the capacity of the
tumor cells to infiltrate and invade into the brain parenchyma was impaired in
vivo (Yiin et al., 2009). Furthermore, the anti-migratory effect of Slit2 on tumor
cells was dependent on Robo1. When glioma cells were transfected with Robo1
siRNA, the anti-migratory effects of recombinant Slit2 was reversed suggesting
that Slit2 inhibited glioma cell migration in a Robo1 dependent manner (Yiin et
al., 2009). Similar findings were observed by Mertsch et al. in which Slit2 reduced
migration of glioma cell lines that was neutralized by RNAi mediated knockdown
of Robo1 in vitro (Mertsch et al., 2008). These observations suggest that Slit2Robo1 has a critical role in glioma cell migration which may be important in
understanding the invasive nature of gliomas. Since glioma cell invasion into the
brain parenchyma is a major contributor to tumor recurrence, a better
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understanding of the cues involved in glioma migration and invasion is essential
for developing effective treatment strategies against malignant gliomas.

Traumatic and Surgical Brain Injury
The role of Slit2 after brain injury has been studied to an even lesser
extent. In a cryo-injured traumatic brain injury mouse model Slit2 was found to be
highly expressed by the neurons and astrocytes surrounding the lesion (Hagino
et al., 2003). Slit2 was the predominant member of the Slit family proteins
expressed in surrounding necrotic tissue following cryo-injury, while Slit1 and
Slit3 showed much weaker expression (Hagino et al., 2003). Slit2 mRNA was
elevated during the early phase of the injury by day 2 and reached a peak at day
7 followed by a decline in expression on day 14 post-injury. The proximal reactive
astrocytes surrounding the lesion expressed Slit2 but not the distal astrocytes,
microglia or oligodendrocytes (Hagino et al., 2003). Furthermore, Slit2 colocalized with the heparan sulfate proteoglycan, glypican-1, indicating a possible
involvement of Slit2-glypican-1 interaction in the recovery after traumatic brain
injury. The heparin sulfate chain of glypican-1 binds with high affinity to Slit2 and
the authors postulated that such a binding may increase the interaction of Slit2
with Robo during recovery after injury. Likewise, we recently published that Slit2
was increased at the perisurgical site following neurosurgical brain injury in a rat
model, and Slit2 was expressed by both neurons and astrocytes (Sherchan et al.,
2015). We speculate that Slit2 likely has a protective function after brain injury,
since knockdown of endogenous Slit2 using siRNA worsened brain edema after
SBI. Additionally, recombinant Slit2 pretreament improved outcomes after
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surgical brain injury by reducing brain edema and neuroinflammation at the
perisurgical site (Sherchan et al., 2015).

Cerebral Ischemia
The inhibitory effect of Slit2 on peripheral leukocyte migration has been a
recent addition to the spectrum of the anti-migratory effects of Slit2 on various
cell types (Wong et al., 2002). Slit2 has been shown to inhibit the migration of
various cell types including neurons, pericytes, endothelial cells, and peripheral
leukoctyes (Wong et al., 2001, Wong et al., 2002). Altay et al. explored the role of
Slit in reducing cerebral leukocyte migration in rodent models (Altay et al., 2007).
Exogenous Slit administration decreased leukocyte adherence by 98% in the
cerebral microvessels 4 hours following TNF exposure (Altay et al., 2007).
Similar effects were observed after experimental global cerebral ischemia in
which 79% reduction in leukocyte adherence was observed (Altay et al., 2007).
Administration of RoboN, the soluble receptor for Slit reversed the inhibitory
effect of Slit on leukocyte migration to the cerebral microvessels after global
ischemia. Additionally, neutralizing endogenous Slit exacerbated TNF induced
cerebral microvessel leukocyte recruitment suggesting an anti-migratory role of
both the endogenous and exogenous Slit following cerebrovascular inflammation
(Altay et al., 2007).

Intracerebral Hemorrhage
A few studies have explored CNS pathology using Slit2 transgenic
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animals. These studies provide evidence that overexpression of Slit2 can be
detrimental. Slit2 overexpressing transgenic mice had increased brain
microvessel density compared to wild type mice and were more susceptible to
collagenase induced ICH (Han and Geng, 2011). The transgenic mice exhibited
larger hemorrhagic areas and increased intracerebral hemorrhage volume
compared to control mice indicating that the vessels in Slit2 transgenic mice were
fragile and susceptible to greater injury given the same degree of insult (Han and
Geng, 2011). There was increased brain microvessel permeability in Slit2
transgenic mice demonstrated by Evans blue dye extravasation and Amyloid-β
40 peptides leakage from serum into the brains of Slit2 transgenic mice but not in
the control wild type mice (Han and Geng, 2011). Additionally, Slit2
overexpressing transgenic mice had enlarged lateral ventricles with higher
ventricular pressure compared to control mice which was associated with
abnormal morphology of the choroid plexus characterized by increase in
microvessls and enlarged interepithelial and endothelial junctions (Han and
Geng, 2011). Likewise, transgenic mice overexpressing human Slit2 exhibited
increased BBB permeability and Alzheimer's disease (AD)-like alterations
characterized by behavioral changes, hippocampal neuron apoptosis, and
amyloid-β (Aβ) protein deposition (Li et al., 2015a).

Epilepsy
In a previous study, Fang et al. characterized the role of Slit2 in synaptic
plasticity after temporal lobe epilepsy. The study evaluated the expression of
Slit2 after temporal lobe epilepsy using temporal neocortex samples from
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patients with intractable temporal lobe epilepsy and in experimental animals
(Fang et al., 2010). While Slit2 was mainly expressed by neurons in normal
human controls, samples taken from patients with intractable temporal lobe
epilepsy showed that Slit2 was increased and expressed by both neurons and
astrocytes (Fang et al., 2010). Similar findings were observed in the experimental
rat model with increased Slit2 expression compared to control rats. Likewise,
Slit2 was expressed by neurons in the controls and during the acute and latent
phase of epilepsy in a rat model. However, during the chronic phase (30 and 60
days) Slit2 was mainly expressed by astrocytes (Fang et al., 2010). The study by
Fang et al. suggests that Slit2 could be an important guidance molecule to direct
axonal sprouting towards the correct target during remodeling phase after
epilepsy (Fang et al., 2010). Additionally, the authors speculated that decreased
expression of Slit2 during acute phase after epilepsy induction with increasing
expression in the astrocytes during chronic phase suggests that Slit2 may be
involved in astrogliosis after epilepsy. Further, investigation into the role of Slit2
after epilepsy is necessary to delineate its function after epilepsy.

Role of Slit2 Dependent on Cell Types
Endothelial Cells
Previous study examining the role of Slit2 on the endothelial cells in CNS
implicates an endothelial protective function of Slit2. The Robo4 receptor is the
endothelial specific receptor for Slit2 that is expressed by human brain
microvascular endothelial cells. Previous study used an in vitro model of glioma
blood-tumor barrier (BTB) to explore the role of Slit2-Robo4 in maintaining BTB
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stability (Cai et al., 2015). The expression of Robo4 was upregulated in human
glioma tissues compared to normal brain tissues as well as in the glioma
cocultured endothelial cells derived from the BTB model (Cai et al., 2015). Slit2
pretreatment reduced BTB endothelial permeability but this protective effect of
Slit2 was not seen in the presence of Robo4 knockdown (Cai et al., 2015).
Additionally, Robo4 overexpression reduced BTB permeability by 50.33% which
was associated with reduced MMP-9 activity and a corresponding increase in the
expression of endothelial tight junction proteins occludin, ZO-1 and claudin-5 (Cai
et al., 2015). Whereas, Robo4 knockdown increased the endothelial BTB
permeability 1.41 times higher compared to the control group and showed the
opposite effect on MMP-9 activity and tight junction protein expression.
Furthermore, Src and Erk1/2 were the downstream mediators involved in
regulation of the MMP-9 activity by Robo4 (Cai et al., 2015).
However, a dual role of Slit2 has been implicated in the vascular
endothelial cells outside of CNS. The endothelial protective function of Slit2Robo4 was observed following intraocular injections of Slit2 in a retinal vascular
hyperpermeability model in mice (Jones et al., 2008). Likewise, Slit2 inhibited
Andes virus induced disruption of endothelial adherens junction proteins in
human pulmonary microvascular endothelial cells (PMECs) (Gorbunova et al.,
2013). However, vascular permeability was increased in Slit2 transgenic mice
subjected to laser-induced CNV and in the HUVECs in vitro (Li et al., 2015b).
These conflicting results suggest that endogenous Slit2 overexpression and
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exogenous Slit2 possibly have diverse functions and mechanisms on the
endothelial cells.
Moreover, the endothelial response to Slit2 seems to be dependent on the
tissue specific expression of the type of Robo receptors. Studies from systemic
pathologies indicate that the expression and function of endothelial Robo4 may
be context dependent and can vary depending on the pathology. For instance,
Robo4 was found to be upregulated in the endothelial cells in various neoplasm
(Cai et al., 2015). The expression of Robo4 was downregulated in virus-infected
human PMECs and it predominantly expressed Robo4 but not Robo1
(Gorbunova et al., 2013). However, the anti-permeability effect of Slit2 was not
observed in the human umbilical vein endothelial cells (HUVECs) which express
similar levels of Robo4 and Robo1 receptors (Gorbunova et al., 2013). These
findings suggest that the endothelial response to Slit2 is dependent on the tissue
specific endothelial cell expression of the type of Robo receptors.

Pericytes
Pericytes are special cell types that provide structural support to the
capillaries and interact with endothelial cells by making direct cell-cell contacts
and through paracrine signals. Pericytes have been shown to play a critical role
during physiological and pathological angiogenesis (Bergers and Song, 2005).
During initial stage of angiogenesis, pericytes detach from the endothelial cells
which enables endothelial cells to migrate into the surrounding extracellular
matrix giving rise to sprouting new vessels (Raza et al., 2010). Slit2 inhibited
platelet derived growth factor (PDGF) induced human brain vascular pericyte
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motility in an in vitro wound healing assay (Guijarro-Munoz et al., 2012). The
pericyte chemorepellent effect of Slit2 was decreased but not abolished by
antibodies blocking the Robo1 and Robo4 receptors which suggested potential
contribution of other receptors (Guijarro-Munoz et al., 2012). Slit2 also inhibited
PDGF-induced lamellipodia formation in the pericytes, features suggestive of a
pro-migratory phenotype (Guijarro-Munoz et al., 2012). Additionally, pericytes
were found to secrete high levels of Slit2 while negligible amounts of Slit1 and
Slit3 were detected. Higher levels of Robo1 and low levels of Robo4 receptors
were detected on the surface of the pericytes (Guijarro-Munoz et al., 2012). The
authors suggested that Slit2 secreted by the pericytes act in an autocrine manner
on the Robo receptors and regulate its function during angiogenesis. Although a
dual role of Slit2 has been implicated in angiogenesis dependent on the type of
endothelial Robo receptor involved, the regulation of pericyte function also
seems to determine the angiogenic regulation by Slit2.

Regulation of Slit2-Robo in the CNS
A few upstream regulators have been identified that modulate the
expression of Slit-Robo in the CNS. However, detailed studies are lacking and
are essential for understanding how Slit-Robo is altered in CNS pathologies and
the implications of such changes. Additionally, these upstream regulators could
be important targets for potential therapeutic manipulation.

Transcription Factors Pax6
Various regulatory genes control the expression of axonal guidance
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molecules and thereby regulate the path that axonal fibers travel along. Among
few studies that have explored the role of regulatory genes and transcription
factors that control expression of Slit and its receptor Robo, the transcription
factor Pax6 seems to play a role in regulating axonal pathfinding during brain
development by regulating the expression of Slit proteins (Tsuchiya et al., 2009).
The expression of Slit1 and Slit2 were downregulated whereas netrin-1 was
upregulated in the dorsal thalamus of Pax6 deficient mice lacking the
transcription factor Pax6 (Tsuchiya et al., 2009). This was associated with
aberrant pattern of axonal projections from the mammillary bodies to the
thalamus and midbrain in Pax6 mutant mice (Tsuchiya et al., 2009). The
expression of Slit3 did not change and was low in both the wild type and mutant
mice. However, the expression patterns of receptor for netrin-1, DCC and Robo13 was similar between Pax mutant and wild type embryonic mice (Tsuchiya et al.,
2009). Mutations in genes that encode the transcription factor Pax6 may lead to
reduced Slit1 and Slit2 expression resulting in abnormal axonal pathfinding.

MicroRNA 218
MicroRNAs (miRNAs) may control the migration and invasion of glioma
cells by regulating the expression of Slit2 and its receptor. MicroRNAs are short
noncoding single-stranded RNAs, ~22 nucleotides in length, that function as
oncogenes or tumor suppressors in various types of cancers. MicroRNA 218
(miR-218) in particular was found to be downregulated in glioma cell lines and in
human glioma tissues (Gu et al., 2015). Transfection of gliom cells with miR-218
inhibited the migration and invasion of glioma cells through modulation of the
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Slit2-Robo1 pathway (Gu et al., 2015). MicroRNA 218 transfection was
associated with increased expression of Slit2 but miR-218 downregulated the
expression of Robo1 in the glioma cells by targeting the 3′-untranslated region
(3′-UTR) of Robo1 (Gu et al., 2015). These findings are similar to previous
studies in which miR-218 was shown to inhibit the invasion and progression of
gastric and nasopharyngeal cancer cells by downregulating the Slit2-Robo1
pathway (Tie et al., 2010, Alajez et al., 2011).

Endocannabinoids and Cannabinoid Receptors
The upstream factors that regulate Slit-Robo signaling, expression and
function remains poorly explored. In the developing brain, Slit2 regulates the
direction of migrating axons specifically by preventing midline crossing and
maintaining the dorsoventral positioning of axons. Endocannabinoids and
cannabinoid receptors 1 and 2 have been implicated as upstream regulators of
Slit2-Robo1interaction during development of the forebrain axonal tracts (Alpar
et al., 2014).

Downstream Targets of Slit2-Robo Signaling in the CNS
Few downstream targets of Slit2-Robo signaling pathways have been
identified in the CNS. These studies provide a glimpse into the intracellular
mechanism by how Slit2 exerts its anti-migratory function in the CNS.

Small Rho-GTPase Cdc42
Various axon guidance cues regulate actin polymerization at the leading
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edge of growth cones during cell motility or axon pathfinding by modulating the
activity of cytoskeletal regulatory proteins. Cdc42 is a member of the small RhoGTPases that regulates actin cytoskeletal polymerization during cellular motility.
Modulation of Cdc42 activity by various guidance cue molecules has been
implicated in directing cell migration (Myers et al., 2012). Yinn et al. showed that
Slit2 regulated Cdc42 activity in glioma cells dependent on Robo1 receptor in
vitro (Yiin et al., 2009). The expression of Slit2 in glioma cells attenuated Cdc42
activity which was reversed with immunodepletion of Slit2. Likewise,
immunodepletion of Slit2 also reversed the effects of Slit2 to inhibit glioma cell
migration (Yiin et al., 2009). Additionally, when glioma cells were transfected with
Robo1 siRNA the effects of recombinant Slit2 to inhibit cell migration and reduce
Cdc42 activity were reversed suggesting that Slit2 inhibited glioma cell migration
by attenuating Cdc42 activity dependent on the Robo1 receptor (Yiin et al.,
2009).

Focal Adhesion Kinase
Previous study showed that Slit2 regulated neuronal motility in a FAK- and
Cdc42-dependent manner in vitro (Myers et al., 2012). Positive guidance cues
such as BDNF and laminin increased Cdc42 activity and enhanced cellular
protrusion, whereas Slit2 decreased Cdc42 activity and lamellipodia formation
thereby reducing neuronal migration, which was disrupted with the expression of
constitutively active FAK (Myers et al., 2012). This implicates that Slit2 regulates
neuronal migration by modulating Cdc42 activity in a FAK-dependent manner.
The downstream effectors of Cdc42 such as p21-activated kinase (PAK) and N
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Wiskott Aldrich Syndrome Protein (N-WASP) modulate actin polymerization and
therefore cell migration (Myers et al., 2012).

Src and Extracellular Signal-Regulated Kinase 1/2
Previous study using a glioma BTB model in vitro showed that Slit2 had
anti-permeability effect on the endothelial cells derived from the BTB. Robo4
knockdown increased the BTB endothelial permeability by disrupting tight
junction proteins which was mediated via the activation of Src-Erk1/2-MMP-9
signaling pathway (Cai et al., 2015). Inhibitors of Src and Erk partially reversed
the increase in BTB permeability and MMP-9 activity induced by Robo4
knockdown, which showed that Src and Erk1/2 are downstream mediators
involved in endothelial Robo4 activation.

Research Question, Hypothesis and Research Aims
Clinical and experimental studies show that adverse events such as brain
edema and neurological deficits occur post-operatively following neurosurgical
procedures. The mechanisms of influx of blood-borne inflammatory cells into
brain parenchyma, which amplifies neuroinflammation and parenchymal damage
as well as BBB disruption, which potentiates brain edema after SBI has been
explored in this project. Specifically, the role of Slit2, an extracellular matrix
protein expressed endogenously in the brain, as well as the effects of
recombinant Slit2 as a novel therapeutic strategy to reduce neuroinflammation
and BBB disruption after SBI has been studied.
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Our central hypothesis was that Slit2 will increase after SBI as an
endogenous protective mechanism, and recombinant Slit2 pretreatment will
reduce neuroinflammation and stabilize the BBB via Robo receptor signaling
pathway in a rat SBI model.
The following three specific aims have been explored in this project.

Specific Aim 1. Evaluate the Role of Slit2 in Reducing Neuroinflammation
and BBB Permeability After SBI
Our corollary hypothesis was that Slit2 will attenuate neuroinflammation
and BBB permeability after SBI, thereby reducing brain edema and neurological
deficits. We measured temporal profile of Slit2 expression after SBI and
evaluated outcomes after endogenous Slit2 knockdown in the SBI rats. Brain
edema, neurological deficits and inflammatory makers were measured with
recombinant Slit2 pretreatment.

Specific Aim 2. Investigate the Role of Slit2 and its Receptor Robo1 in
Reducing Neuroinflammation After SBI
Our corollary hypothesis was that Slit2 will attenuate neuroinflammation
after SBI by reducing peripheral leukocyte infiltration by Robo1-srGAP1 mediated
Cdc42 inactivation. We measured inflammatory mediators and leukocyte
infiltration after SBI and with recombinant Slit2 pretreatment. The effect of
antagonizing Robo1 and its downstream effector srGAP1 with recombinant Slit2
pretreatment was also evaluated.
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Specific Aim 3. Investigate the Role of Slit2 and its Receptor Robo4 in
Stabilizing the BBB After SBI
Our corollary hypothesis was that Slit2 will protect BBB integrity after SBI
by stabilizing the BBB junction proteins through Robo4-paxilin mediated Rac1
activation. We measured the expression of BBB junction proteins after SBI and
with recombinant Slit2 pretreatment. The effect of antagonizing Robo4 and its
downstream effector paxilin with recombinant Slit2 pretreatment was also
evaluated.
The schematic representation of specific aims (Fig. 1) illustrates the key
players examined in this project.
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Figure 1. Schematic representation of specific aims. Surgical brain injury (SBI)
leads to peripheral immune cell infiltration at the perisurgical site and disruption of
the blood brain barrier (BBB) tight junction (TJ) and adherens junction (AJ)
proteins. This potentiates brain edema at the perisurgical site and consequently
neurological dysfunction. Aim 1 evaluated the role of endogenous Slit2 after SBI.
Next the protective effects of recombinant Slit2 on neuroinflammation and BBB
permeability were evaluated. Aim 2 evaluated the mechanism by which Slit2
reduces neuroinflammation after SBI. Aim 3 evaluated the mechanism by which
Slit2 decreases BBB permeability after SBI.
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Abstract
Background and Purpose: Peripheral immune cell infiltration to the brain
tissue at the perisurgical site can promote neuroinflammation after surgical brain
injury (SBI). Slit2, an extracellular matrix protein, has been reported to reduce
leukocyte migration. This study evaluated the effect of recombinant Slit2 and the
role of its receptor roundabout1 (Robo1) and its downstream mediator Slit-Robo
GTPase activating protein 1 (srGAP1)-Cdc42 on peripheral immune cell
infiltration after SBI in a rat model.
Methods: One hundred and fifty-three adult male Sprague-Dawley rats
(280-350 g) were used. Partial resection of right frontal lobe was performed to
induce SBI. Slit2 siRNA was administered by intracerebroventricular injection 24
hours before SBI. Recombinant Slit2 was injected intraperitoneally 1 hour before
SBI. Recombinant Robo1 used as a decoy receptor was co-administered with
recombinant Slit2. srGAP1 siRNA was administered by intracerebroventricular
injection 24 hours before SBI. Post-assessments included brain water content
measurement, neurological tests, ELISA, western blot, immunohistochemistry,
and Cdc42 activity assay.
Results: Endogenous Slit2 was increased after SBI. Robo1 was
expressed by peripheral immune cells. Endogenous Slit2 knockdown worsened
brain edema after SBI. Recombinant Slit2 administration reduced brain edema,
neurological deficits, and pro-inflammatory cytokines after SBI. Recombinant
Slit2 reduced peripheral immune cell markers cluster of differentiation 45 (CD45)
and myeloperoxidase (MPO), as well as Cdc42 activity in the perisurgical brain
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tissue which was reversed by recombinant Robo1 co-administration and srGAP1
siRNA.
Conclusions: Recombinant Slit2 improved outcomes by reducing
neuroinflammation after SBI, possibly by decreasing peripheral immune cell
infiltration to the perisurgical site through Robo1-srGAP1 mediated inhibition of
Cdc42 activity. These results suggest that Slit2 may be beneficial to reduce SBIinduced neuroinflammation.

Keywords
Surgical brain injury, Neuroinflammation, Brain edema, Peripheral
Immune Cell Infiltration, Slit2, Robo1, srGAP1, Cdc42.

Highlights
Peripheral immune cells infiltration increased at the perisurgical site after SBI
Endogenous Slit2 was increased as a protective mechanism after SBI
Recombinant Slit2 attenuated brain edema by reducing neuroinflammation
Recombinant Slit2 reduced neuroinflammation by decreasing immune cell
infiltration
Recombinant Slit2 inhibited immune cell migration dependent on Robo1SrGAP1 pathway
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Introduction
Surgical brain injury (SBI) is the inadvertent injury to brain tissue at the
perisurgical site which occurs due to neurosurgical maneuvers such as incision,
retraction, and electrocoagulation that can aggravate post-operative brain edema
and neurological deficits (Jadhav et al., 2007a, Huang et al., 2014). Major
complications are encountered in 13-27% patients after intracranial surgeries
(Bruder, 2002). Measures to reduce neurosurgical complications are limited
(Jadhav et al., 2007a). Furthermore, routine therapy used against SBI including
hyperosmolar agents and steroids can have unwanted adverse effects (Li et al.,
2014, Xu et al., 2014). Therapeutic strategies that augment endogenous
protective mechanisms would be a safe approach to reduce post-operative
complications in neurosurgical patients.
Neuroinflammation is a major pathophysiological consequence after SBI
(Yamaguchi et al., 2007, Hyong et al., 2008) which contributes to brain edema
that can worsen post-operative neurological function (Ayer et al., 2012).
Following brain injury, resident immune cells get activated and release cytokines
and chemokines that promote migration of peripheral immune cells to injury site
in the brain (Wang and Dore, 2007, Rhodes, 2011, Ma et al., 2014). Immune cell
infiltration and inflammatory mediators were increased in adjacent brain tissue at
the perisurgical site following experimental resection (Jadhav et al., 2007a,
Hyong et al., 2008). Infiltrated immune cells release inflammatory mediators that
further promote neuroinflammation (Petty and Lo, 2002, Yilmaz et al., 2006, Lo,
2009).
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Slit2 is a secreted extracellular matrix protein (Ballard and Hinck, 2012)
expressed endogenously in the brain by neurons and astrocytes (Hagino et al.,
2003, Prasad et al., 2007). Slit2 was recently identified as an inhibitor of
leukocyte chemotaxis (Wu et al., 2001, Ballard and Hinck, 2012) and was shown
to be protective in experimental models of systemic inflammation (Kanellis et al.,
2004, Tole et al., 2009, London et al., 2010). Slit2 reduced migration of
leukocytes to the cortical venules after global cerebral ischemia in mice (Altay et
al., 2007). The anti-migratory function of Slit2 is mediated by binding to its
receptor roundabout1 (Robo1) (Wong et al., 2002, Ballard and Hinck, 2012).
Furthermore, it has been established that Slit-Robo GTPase Activating Protein 1
(srGAP1) a downstream effector of the receptor Robo1 (Wong et al., 2002) can
inhibit Cdc42, which is a critical mediator for cell migration (Bishop and Hall,
2000, Yiin et al., 2009). Robo1 has been shown to be expressed on the surface
of peripheral immune cells (Wu et al., 2001, Guan and Rao, 2003, Prasad et al.,
2007), which we propose induces the signal transduction pathway that mediates
the anti-migratory effect of Slit2 and thereby reduces brain infiltration of
peripheral immune cells.
The role of Slit2 after SBI is unknown, and the mechanism by which Slit2
elicits neuroprotection has not been evaluated. The objective of this study was to
evaluate the effects of recombinant Slit2 as a novel therapeutic strategy to
reduce neuroinflammation after SBI in a rat model.
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Materials and Methods
Animals
All procedures were approved by the Institutional Animal Care and Use
Committee at Loma Linda University and complied with NIH Guide for the Care
and Use of Laboratory Animals. Adult male Sprague Dawley rats (280–350 g)
were housed in humidity and temperature controlled environment with 12 hour
light/dark cycle. One hundred and fifty-three rats were subjected to either Sham
surgery (n=26) or SBI surgery (n=127) by inducing partial resection of the right
frontal lobe.

Experimental Design
Experiment 1. The time course expression and localization of endogenous
Slit2 and Robo1 was characterized at 24 hours, 72 hours, and day 7 after SBI.
Rats (n=24) were divided 4 groups: Sham, SBI 24 hours, SBI 72 hours, and SBI
day 7. Brain samples from the residual right frontal lobe were collected for
enzyme linked immunosorbent assay (ELISA), western blot and for
immunohistochemistry.
Experiment 2. The role of endogenous Slit2 after SBI was evaluated. Rats
(n=37) were divided into 4 groups: Sham, SBI, SBI+Slit2 siRNA, SBI+Scramble
siRNA. Endogenous Slit2 knockdown was performed by intracerebroventricular
(ICV) injection of Slit2 siRNA (Life Technologies, Grand Island, NY, USA) 24
hours before SBI. Brain water content, neurological function and western blot
was evaluated at 72 hours after surgery.
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Experiment 3. The effect of exogenous recombinant Slit2 pretreatment for
SBI was evaluated. Three doses of recombinant Slit2 (1 µg/Kg, 3 µg/Kg, 10
µg/Kg) (R and D Systems, Minneapolis, MN, USA) was tested. Rats (n=74) were
divided into 5 groups: Sham, SBI+Vehicle, SBI+Slit2 (1 µg/Kg), SBI+Slit2 (3
µg/Kg), SBI+Slit2 (10 µg/Kg). The dose of recombinant Slit2 (3 μg/Kg) was
chosen based on previous publication (Altay et al., 2007). Furthermore, since a
dose response effect of Slit2 was previously reported in vitro studies (Prasad et
al., 2007), we examined the effects of two additional doses to establish the
optimal dose for SBI. Recombinant Slit2 or vehicle normal saline was injected
intraperitoneally 1 hour before SBI. Brain water content and neurological function
was evaluated at 24 and 72 hours after surgery. Brain samples from the residual
right frontal lobe at the perisurgical site were collected at 24 hours for western
blot and immunohistochemistry.
Experiment 4. The role of Robo1 and srGAP1 in recombinant Slit2
mediated protection after SBI was investigated. Rats were divided into 6 groups:
Sham, SBI+Vehicle, SBI+Slit2 (10 µg/Kg), SBI+Slit2(10 µg/Kg)+Robo1(3 µg/Kg),
SBI+Slit2(10 µg/Kg)+srGAP1 siRNA, SBI+Slit2(10 µg/Kg)+scramble siRNA. Rats
(n=18) were added for the last 3 groups. Recombinant Robo1 (3 µg/Kg) (R and D
Systems, Minneapolis, MN, USA) was co-administered with recombinant Slit2 by
intraperitoneal injection 1 hour before SBI. srGAP1 or scramble siRNA (Life
Technologies, Grand Island, NY, USA) was given by ICV injection 24 hours
before SBI. Neurological function was evaluated at 24 hours after surgery and
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brain samples were collected at 24 hours for western blot and Cdc42 activity
assay.

Surgical Brain Injury Model
Rats were subjected to surgical brain injury as previously described
(Jadhav et al., 2007a, Yamaguchi et al., 2007). Briefly, anesthesia was induced
by 4% isoflurane in an induction chamber and maintained at 2.5% using a nasal
mask. The skin was incised and periosteum was reflected to expose the bregma
and frontal bone. A square craniotomy 5x5 mm was made on the right frontal
bone with left lower corner towards bregma by using a micro drill. The dura was
incised and a partial resection of the right frontal lobe was performed with
margins of resection at 2 mm lateral to sagittal suture and 1 mm proximal to
coronal suture, with the depth extending to base of skull. Normal saline irrigation
and intraoperative packing was done to ensure complete hemostasis after which
skin incision was sutured. Sham animals were subjected to right frontal
craniotomy but without dural incision or frontal lobe resection. Buprenorphine
0.03 mg/Kg was given by subcutaneous injection for post-operative analgesia.
Post-operatively rats were closely observed for complete recovery from
anesthesia.

Intracerebroventricular Injection
Rats were anesthetized with isoflurane and placed prone on a stereotactic
frame. A 10 µL Hamilton syringe (Hamilton Co, Reno, NV, USA) was inserted
through a burr hole on the skull into right lateral ventricle using the following
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coordinates relative to bregma: 1.0 mm lateral, 1.5 mm posterior and 3.2 mm
below the horizontal plane of bregma as previously described (Suzuki et al.,
2010, Chen et al., 2013). Slit2 siRNA 500 pmol or srGAP1 siRNA 500 pmol (Life
Technologies, Grand Island, NY, USA) each in 2 μL sterile saline was injected at
a rate 0.5 μL/min as previously described (Suzuki et al., 2010, Chen et al., 2013).
The same volume of scramble siRNA (Life Technologies, Grand Island, NY,
USA) was injected as a negative control. The needle was left in situ for additional
10 mins and then slowly withdrawn over 5 mins to prevent leakage. The burr hole
was sealed with bone wax and skin incision was sutured. Rats were returned to
recovery cages and closely observed for complete recovery from anesthesia.

Brain Water Content Measurement
Brain edema was evaluated at 24 and 72 hours after surgery by wet
weight/dry weight method as previously described (Jadhav et al., 2007b,
Yamaguchi et al., 2007). The brains were quickly removed and dissected into six
parts: right frontal, left frontal, right parietal, left parietal, cerebellum and
brainstem. The samples were weighed immediately (wet weight) and then placed
in an oven at 100°C for 48 hours and weighed again (dry weight). The percent of
brain water content in each region was calculated using the formula [(wet weight
– dry weight)÷wet weight]×100 (Yamaguchi et al., 2007).

Assessment of Neurological Function
Neurobehavioral deficits were evaluated by an examiner blinded to the
groups by using modified Garcia test and beam balance test at 24 and 72 hours
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after SBI as previously described (Garcia et al., 1995, Yamaguchi et al., 2007).
Briefly, Garcia test assessed sensorimotor deficits and included seven tests:
spontaneous activity, body proprioception, vibrissae touch, limb symmetry, lateral
turning, forepaw outstretching, and climbing. Each test was scored from 0 to 3
with a maximum score of 21. In beam balance test, the rats were allowed to walk
on a 90 cm x 2.25 cm beam for 1 min during which distance traveled and time
taken to travel the distance was recorded. The score ranged from 0 to 5. Higher
scores indicated better function for both the tests.

Enzyme Linked Immunosorbent Assay (ELISA)
Slit2 concentration in brain samples were measured using a Slit2-HRP
conjugated Elisa kit (MyBiosource, San Diego, CA, USA) as previously described
(Doyle et al., 2008, Hu et al., 2014). Sample supernatants from the residual right
frontal lobe were incubated in a microtiter plate pre-coated with biotin conjugated
antibody specific for rat Slit2. Next, the samples were incubated with avidin
conjugated HRP after which TMB substrate was added. The absorbance was
measured spectrophotometrically at wavelength of 450 nm using a microplate
reader (Biorad, Irvine, CA, USA).

Western Blotting
Western blot was performed as previously described (Hasegawa et al.,
2011, Chen et al., 2013). Briefly, brain samples were collected after rats were
transcardially perfused with phosphate buffered saline (PBS). Samples were
homogenized in Ripa lysis buffer (Santa Cruz Biotechnology, Dallas, TX, USA)
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for protein extraction (Hasegawa et al., 2011) Supernatants from the residual
right frontal lobe samples were collected after centrifugation at 14,000 g at 4oC
for 30 mins and protein concentration was determined using a detergent
compatibility assay (Biorad, Irvine, CA, USA). Equal amounts of protein (50 µg)
were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
and then transferred onto nitrocellulose membranes after which the membranes
were incubated overnight with the respective primary antibodies: anti-Slit2
(1:200), anti-Robo1 (1:200), anti-myeloperoxidase (MPO) (1:500) (all from Santa
Cruz Biotechnology, Dallas, TX, USA), anti-cluster of differentiation 45 (CD45)
(1:500), anti-IL-1β (1:1000) and anti-INF-γ (1:1000) (all from Abcam, Cambridge,
MA, USA). The same membranes were probed with anti-β Actin (1:2000) (Santa
Cruz Biotechnology, Dallas, TX, USA) as loading controls. The membranes were
incubated with appropriate secondary antibodies (1:4000) (Santa Cruz
Biotechnology, Dallas, TX, USA) for 1 hour at room temperature. Bands were
visualized using ECL Plus Chemiluminescence kit (Amersham Biosciences,
Arlington Heights, IL, USA) and quantified using the software Image J (National
Institutes of Health, Bethesda, MD, USA). Results are expressed as relative
density to β-actin and then normalized to average value of the sham group as
previously described (Hasegawa et al., 2011).

Immunohistochemistry
Briefly, after PBS perfusion and post-fixation in formalin, brain samples
were sectioned into 10-µm-thick slices using a cryostat (CM3050S; Leica
Microsystems, Bannockburn, IL, USA). Immunofluorescence staining was
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performed as previously described (Hasegawa et al., 2011, Altay et al., 2012).
The sections were incubated overnight at 4oC with the following primary
antibodies: anti-Slit2 (1:200), anti-Robo1 (1:200), anti-MPO (1:200) (all from
Santa Cruz Biotechnology, Dallas, TX, USA), anti-neuronal nuclei (NeuN)
(1:500), anti-glial fibrillary acidic protein (GFAP) (1:100) and anti-CD45 (1:150)
(all from Abcam, Cambridge, MA, USA). Sections were then incubated with
FITC- and Texas Red-conjugated appropriate secondary antibodies (1:100)
(Jackson Immuno Research, West Grove, PA, USA) for 2 hours at room
temperature and visualized with a fluorescence microscope (Olympus BX51).

Cdc42 Activity Assay
A pull down assay was performed using Cdc42 activity assay kit (Cell
Biolabs, San Diego, CA, USA) as previously described (Yiin et al., 2009). Briefly,
samples were mixed with the p21-activated protein kinase (PAK1)-p21-binding
domain (PBD) agarose beads and incubated at 4oC for 1 hour. The beads were
then re-suspended in sample buffer and separated by 10% polyacrylamide gel
electrophoresis and then transferred to a nitrocellulose membrane. The
membrane was probed with anti-Cdc42 specific antibody provided in the kit to
detect the GTP-bound Cdc42.

Statistical Analysis
Statistical analysis was performed using the Sigma Plot 10.0 and Sigma
Stat version 3.5 (Systat Software, San Jose, CA, USA). Data were presented as
mean ± SEM. Statistical differences between groups were analyzed using one52

way ANOVA for multiple comparisons followed by Tukey or Student-NewmanKuels post hoc tests. P values less than 0.05 was considered statistically
significant.

Results
All sham-operated rats survived. Nine rats died of the 127 SBI rats. The
overall mortality in the SBI group was 7.09%.

Temporal Expression and Localization of Endogenous Slit2
After SBI
The expression of Slit2 at the perisurgical site in the brain was measured
at 24 hours, 72 hours and 7 days after SBI. The level of endogenous Slit2 was
increased at 24 hours following SBI and reached a peak at 72 hours compared to
sham (p<0.05 compared to sham, Fig. 1A). The increase in the level of Slit2 was
sustained to 7 days after SBI (p<0.05 compared to sham). Double
immunofluorescence staining showed that Slit2 was expressed by the neurons
and astrocytes (Fig. 1C).
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Figure 1. Temporal expression and localization of endogenous Slit2 in the brain
after SBI. (A) ELISA showed that Slit2 concentration increased at 24 hours, 72
hours and 7 days after SBI with a peak at 72 hours. Data are expressed as mean
± SEM. N=4 to 6 per group. ANOVA, SNK. *p<0.05 compared to Sham, φp<0.05
compared to 24 hours SBI. (B) Histology section showing perisurgical site in the
inset used for immunofluorescence staining. (C) Representative microphotographs
of immunofluorescence staining showing co-localization of Slit2 (Texas Red/red),
with neuronal nuclei (NeuN) or glial fibrillary acidic protein (GFAP) (FITC/green)
and DAPI at 24 hours after SBI. Arrows indicate merged cells. Scale bar=50 μm.
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Temporal Expression and Localization of Robo1 After SBI
The expression of Robo1 in the brain was measured at 24 hours, 72 hours
and 7 days after SBI. Robo1 expression increased at all-time points with a peak
at 24 hours after SBI (p<0.05 compared to sham, Fig. 2A). Double
immunofluorescence staining of brain samples showed that Robo1 co-localized
with the marker for peripheral immune cells, cluster of differentiation 45 (CD45)
and with the marker for neutrophils, myeloperoxidase (MPO) at the perisurgical
site after SBI (Fig. 2B).
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Figure 2. Temporal expression and localization of Robo1 in the brain after SBI.
(A) Representative image of western blot and quantitative analysis showed that
Robo1 expression increased at 24 hours, 72 hours and 7 days after SBI with a
peak increase at 24 hours. Data are expressed as mean ± SEM. N=4/group.
ANOVA, SNK. *p<0.05 compared to Sham, φp<0.05 compared to 24 hours SBI.
(B) Representative microphotographs of immunofluorescence staining showing
co-localization of Robo1 (Texas Red/red) with immune cell markers cluster of
differentiation 45 (CD45) or neutrophil marker myeloperoxidase (MPO)
(FITC/green) and DAPI at 24 hours after SBI. Arrows indicate merged cells. Scale
bar=50 μm
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Endogenous Slit2 Knockdown Worsened Outcomes After
SBI
Western blot showed that Slit2 siRNA effectively suppressed the
expression of Slit2 (p<0.05 compared to SBI and scramble siRNA groups, Fig.
3A). SBI rats that received Slit2 siRNA had significantly higher brain water
content in the residual right frontal lobe (p<0.05 compared to SBI and scramble
siRNA groups, Fig. 3B). Garcia test showed worsened neurological function in
the Slit2 siRNA group compared to scramble siRNA (p<0.05 compared to
scramble siRNA, Fig. 3C), but there was no significant difference between the
groups in beam balance test (Fig. 3D).
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Figure 3. Effect of endogenous Slit2 knockdown on Slit2 expression, brain water
content and neurological function 72 hours after SBI. (A) Representative image of
western blot and quantitative analysis of Slit2 expression after siRNA knockdown
showed that Slit2 siRNA but not scramble siRNA significantly reduced the
expression of endogenous Slit2 after SBI. (B) Brain water content was significantly
increased at the residual right frontal lobe 72 hours after SBI. Slit2 siRNA
worsened brain edema compared to SBI and scramble siRNA. RF: right frontal,
LF: left frontal, RP: right parietal, LP: left parietal, C: cerebellum, BS: brainstem.
(C) Garcia test and (D) Beam balance test showed significantly worse neurological
function 72 hours after SBI compared to sham. Slit2 siRNA group performed worse
than scramble siRNA group in the Garcia test. Data are expressed as mean ±
SEM. N=6/group. ANOVA, SNK. *p<0.05 compared to sham, †p<0.05 compared
to SBI, #p<0.05 compared to SBI+scramble siRNA.
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Recombinant Slit2 Administration Reduced Brain Edema and
Improved Neurological Function 24 and 72 Hours After SBI
Brain water content was significantly increased at the perisurgical site in
the residual right frontal lobe at 24 and 72 hours after SBI (p<0.05 compared to
sham, Fig. 4A and 4B, respectively). Recombinant Slit2 3 µg/Kg and 10 µg/Kg
significantly reduced brain water content at both time points (p<0.05 compared to
vehicle). Neurological function evaluated by Garcia test was significantly worse at
24 and 72 hours after SBI (p<0.05 compared to sham, Fig. 4C and 4D,
respectively). All three doses of recombinant Slit2 significantly improved Garcia
scores at 24 hours (p<0.05 compared to vehicle). However, only recombinant
Slit2 10 µg/Kg improved performance in the Garcia test at 72 hours (p<0.05
compared to vehicle). Beam balance test showed significantly worse neurological
function after SBI at 24 and 72 hours (p<0.05 compared to sham, Fig. 4E and 4F,
respectively). Slit2 10 µg/Kg showed a tendency to improve beam balance
scores at 72 hours but was not significant.
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Figure 4. Effect of recombinant Slit2 on brain water content and neurological
function at 24 and 72 hours after SBI. Brain water content was significantly
increased in the residual right frontal lobe at 24 hours (A) and 72 hours (B) after
SBI. Recombinant Slit2 3 µg/Kg and 10 µg/Kg significantly reduced brain edema
at both time points. RF: right frontal, LF: left frontal, RP: right parietal, LP: left
parietal, C: cerebellum, BS: brainstem. Garcia test (C and D) and Beam balance
test (E and F) showed significantly worse neurological function at 24 and 72 hours
after SBI, respectively. Slit2 10 µg/Kg significantly improved performance in the
Garcia test 24 and 72 hours after SBI. Data are expressed as mean ± SEM.
ANOVA, Tukey. *p<0.05 compared to Sham, †p<0.05 compared to SBI+Vehicle,
‡p<0.05 compared to SBI+Slit2 10 µg/Kg.
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Recombinant Slit2 Reduced Neuroinflammation and Peripheral
Immune Cell Infiltration at the Perisurgical Site 24 Hours After SBI
The expression of pro-inflammatory cytokines IL-1β and INF-γ in the
residual right frontal lobe was quantified by western blot, which showed
significant increase after SBI compared to sham (P<0.05 compared to sham, Fig.
5A and 5B, respectively). Recombinant Slit2 10 µg/Kg significantly reduced the
expression of both IL-1β and INF-γ (p<0.05 compared to vehicle).
Immunofluorescence staining showed increased CD45 and MPO positive cells at
the perisurgical site after SBI compared to sham (Fig. 5C and 5D, respectively).
Recombinant Slit2 10 µg/Kg treated group had fewer cells positively stained for
CD45 and MPO compared to vehicle group.
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Figure 5. Effect of recombinant Slit2 on neuroinflammation and peripheral immune
cell infiltration at 24 hours after SBI. Representative western blot image and
quantitative analysis showed that IL-1β (A) and INF-γ (B) expression was
significantly increased after SBI. Slit2 10 μg/Kg significantly reduced the
expression of both pro-inflammatory cytokines. Data are expressed as mean ±
SEM. N=6/group. ANOVA, SNK. *p<0.05 compared to Sham, †p<0.05 compared
to SBI+Vehicle. (C) Representative microphotographs of immunofluorescence
staining showing co-localization of peripheral immune cell marker cluster of
differentiation 45 (CD45)-FITC/green with DAPI at the right frontal perisurgical site.
Recombinant Slit2 10 μg/Kg group had fewer CD45 positively stained cells. (D)
Representative microphotographs of immunofluorescence staining showing colocalization of neutrophil marker myeloperoxidase (MPO)-FITC/green with DAPI at
the perisurgical site. Fewer MPO positive cells were visualized in the recombinant
Slit2 10 μg/Kg group. Asterix denotes site of injury and scale bar=100 μm for
panels C and D.
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Recombinant Slit2 Reduced Peripheral Immune Cell Infiltration to the
Perisurgical Site Dependent on Robo1 Receptor and its Downstream
Mediator srGAP1
Western blot showed that CD45 and MPO expression was significantly
increased after SBI (p<0.05 compared to sham, Fig. 6A and 6B, respectively).
Recombinant Slit2 10 µg/Kg significantly reduced the expression of both markers
(p<0.05 compared to vehicle). Recombinant Robo1 administration abolished the
effects of recombinant Slit2 by increasing expression of CD45 and MPO (p<0.05
compared to Slit2) and worsened neurological deficits which was evaluated using
Garcia test (p<0.05 compared to Slit2, Fig. 6C). Likewise, srGAP1 siRNA
abolished the effects of recombinant Slit2 by increasing the expression of CD45
and MPO (p<0.05 compared to Slit2, Fig 7A and 7B, respectively) and worsened
neurological deficits which was evaluated using Garcia test (p<0.05 compared to
Slit2, Fig 7C).
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Figure 6. Role of Robo1 in Slit2 mediated decrease in peripheral immune cell
infiltration. (A) Representative western blot image and quantitative analysis
showing peripheral immune cell marker cluster of differentiation (CD45)
expression was increased in the right frontal perisurgical site at 24 hours after SBI
compared to sham. Slit2 10 μg/Kg significantly reduced the expression of CD45
which was reversed with recombinant Robo1 co-administration. (B)
Representative western blot image and quantitative analysis showing increased
expression of neutrophil marker myeloperoxidase (MPO) at the perisurgical site
after SBI. Slit2 10 μg/Kg significantly reduced the expression of MPO which was
reversed with recombinant Robo1 co-administration. (C) Slit2 10 μg/Kg
significantly improved neurological function evaluated using Garcia test 24 hours
after SBI which was reversed with recombinant Robo1 co-administration. Data are
expressed as mean ± SEM, N=6/group. ANOVA, SNK. *p<0.05 compared to
Sham, †p<0.05 compared to SBI+Vehicle, &p<0.05 compared to SBI+Slit2 10
μg/Kg.
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Figure 7. Role of srGAP1 in Slit2 mediated decrease in peripheral immune cell
infiltration. (A) Representative western blot image and quantification showing Slit2
10 μg/Kg significantly reduced the expression of peripheral immune cell marker
cluster of differentiation 45 (CD45) which was reversed with srGAP1 siRNA but not
scramble siRNA. (B) Slit2 10 μg/Kg significantly reduced the expression of
neutrophil marker myeloperoxidase (MPO) which was reversed with srGAP1
siRNA but not scramble siRNA. (C) Slit2 10 μg/Kg significantly improved
neurological function evaluated using Garcia test 24 hours after SBI which was
reversed with srGAP1 siRNA. Data are expressed as mean ± SEM, N=6/group.
ANOVA, SNK. †p<0.05 compared to SBI+Vehicle, &p<0.05 compared to SBI+Slit2
10 μg/Kg, @p<0.05 compared to SBI+Slit2+srGAP1 siRNA.
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Recombinant Slit2 Reduced Cdc42 Activity After SBI by
Robo1-srGAP1 Pathway
Cdc42 activity was significantly increased 24 hours after SBI (p<0.05
compared to sham, Fig. 8A), which was reduced with recombinant Slit2 10 µg/Kg
administration (p<0.05 compared to vehicle). Recombinant Robo1 3 µg/Kg
partially reversed the reduction in Cdc42 activity by recombinant Slit2 (p=0.097
compared to SBI+Slit2 10 μg/Kg, Fig. 8A), whereas srGAP1 siRNA reversed the
reduction in Cdc42 activity by recombinant Slit2 (p<0.05 compared to Slit2, Fig.
8B).
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Figure 8. Cdc42 activity assay in the right frontal perisurgical site at 24 hours after
SBI. (A) Cdc42 activity was increased 24 hours after SBI which was significantly
reduced by recombinant Slit2 10 μg/Kg. Robo1 co-administration partially reversed
the effect of Slit2 on Cdc42 activity (p=0.097 compared to SBI+Slit2 10 μg/Kg). (B)
srGAP1 siRNA but not scramble siRNA reversed the effect of Slit2 on Cdc42
activity. Data are expressed as mean ± SEM. N=5/group. ANOVA, SNK. *p<0.05
compared to Sham, †p<0.05 compared to SBI+Vehicle, &p<0.05 compared to
SBI+Slit2 10 μg/Kg, @p<0.05 compared to SBI+Slit2+srGAP1 siRNA.
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Discussion
In this study we focused on the anti-inflammatory function of recombinant
Slit2 after SBI, particularly in terms of reducing peripheral immune cell migration
to the brain after injury. We observed that endogenous Slit2 was upregulated
after SBI, and knockdown of endogenous Slit2 worsened SBI induced brain
edema. Robo1, the receptor for Slit2 was expressed by brain infiltrated peripheral
immune cells. Administration of recombinant Slit2 prior to inducing SBI reduced
brain edema, neurological deficits, neuroinflammation, and peripheral immune
cell infiltration at the perisurgical site. Recombinant Slit2 reduced immune cell
infiltration and Cdc42 activity after SBI was reversed by recombinant Robo1 coadministration as well as by inhibition of the downstream effector srGAP1. These
results suggest that Slit2 may have protective function after SBI, and that
recombinant Slit2 may be a beneficial candidate to reduce neuroinflammation.
Among members of the Slit family, Slit2 has important function in the brain
especially in regulating migration of neurons and axons in the CNS during
development (Marillat et al., 2002). However, its function in the adult brain is still
being explored (Hagino et al., 2003). In addition, there are limited studies on the
effect of Slit2 on neuroinflammation after brain injuries (Altay et al., 2007). Slit2
was detected at the peri-lesional site 2 days after traumatic brain injury and
peaked at 7 days followed by a subsequent decline by day 14 after the injury in
mice (Hagino et al., 2003). Consistent with these studies, our results showed that
endogenous Slit2 increased at 24 hours, 72 hours and 7 days after SBI with a
peak at 72 hours after injury. Slit2 was localized in neurons and astrocytes, which
we speculate is the source for increase in endogenous Slit2 after SBI. This
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observation complements previous studies that have reported Slit2 was
expressed in the neurons and astrocytes (Hagino et al., 2003, Mertsch et al.,
2008).
Roundabout 1 (Robo1), the receptor for Slit2 has been shown to mediate
the anti-migratory function of Slit2 (Prasad et al., 2007, Yiin et al., 2009). Studies
show that Slit2 exerts its repellent function on various cell types by binding to its
receptor Robo1 (Guan and Rao, 2003). Robo1 is highly expressed by neutrophils
(Tole et al., 2009) and lymphocytes (Wu et al., 2001) and moderately expressed
by monocytes (Prasad et al., 2007). We observed that Robo1 expression
increased at the perisurgical site after SBI and peaked at 24 hours and started
decreasing 72 hours after injury. Robo1 was co-localized with the brain infiltrated
peripheral immune cells.
To elucidate the role of endogenous Slit2 after SBI, we performed siRNA
knockdown of endogenous Slit2 and evaluated brain edema and neurological
function at 72 hours after SBI since endogenous Slit2 levels peaked at this time
point. Slit2 knockdown worsened brain edema after SBI. However, there was no
significant difference in neurological function after Slit2 siRNA knockdown
compared to the SBI group. Given that Garcia test and beam balance test
examine the overall gross sensorimotor deficits, it is possible that these tests
were not sensitive enough to detect fine sensorimotor deficits which may result
from the perisurgical site edema (Krafft et al., 2014, McBride et al., 2015).
Additionally, these tests include parameters that evaluate function of the bilateral
side and it is likely that the rats compensated for deficits using the uninjured side
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which may have reduced sensitivity of these tests (Krafft et al., 2014).
Nevertheless, our observations suggest that Slit2 is upregulated in response to
brain injury possibly as an endogenous protective mechanism after SBI.
Endogenous Slit2 may be protective after SBI in several ways. First, Slit2 is a
secreted protein (Marillat et al., 2002) that may be secreted into the CSF and
thence into blood stream where it may directly bind to Robo1 receptors on
peripheral immune cells and thereby eventually slow down migration of these
cells to the brain parenchyma. Interestingly, we observed that Robo1 expression
started decreasing as the levels of endogenous Slit2 temporally increased after
SBI. We speculate that Robo1 expression possibly decreased at 72 hours after
SBI as a result of reduced immune cell infiltration by endogenous Slit2.
Endogenous Slit2 may be elevated as a potential compensatory mechanism after
injury. Second, it is possible that endogenous Slit2 may be increased to
compensate for the endothelial barrier breakdown after injury. Slit2 was shown to
reduce endothelial barrier permeability through binding to the endothelial specific
receptor Robo4 (Jones et al., 2008, Jones et al., 2009). We speculate that Slit2
may be a compensatory mechanism to prevent further breakdown of the blood
brain barrier, which could also reduce peripheral immune cell infiltration to the
brain parenchyma after SBI. This could likely explain why endogenous Slit2
knockdown worsened brain edema. Lastly, Slit2 may exert direct antiinflammatory effects by interacting with the Robo4 receptor. Previous study
showed that Slit2 reduced pro-inflammatory cytokine and chemokine expression
by directly interacting with the endothelial specific Robo4 receptor (Zhao et al.,
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2014). Although we did not investigate the protective mechanism of endogenous
Slit2 after SBI, our results suggest that Slit2 has a protective function after SBI.
Further investigation is needed to explore protective mechanism of endogenous
Slit2 and the role of endothelial Robo4 receptor in Slit2 mediated protection.
Given that Slit2 has a protective function after SBI, next we examined
whether exogenous recombinant Slit2 administration would have beneficial
effects after SBI. Recombinant Slit2 was shown to protect against various
systemic inflammatory conditions including renal, peritoneal and lung
inflammation in rodents (Kanellis et al., 2004, Tole et al., 2009, Ye et al., 2010).
Since neurosurgical procedures are planned events, it allows for pretreatment
before injury is inflicted. Three doses of recombinant Slit2 were tested by
evaluating outcomes at 24 and 72 hours after injury to establish the most
effective dose to reduce SBI. Recombinant Slit2 10 µg/Kg reduced brain edema
and improved performance in the Garcia test at both 24 and 72 hours after SBI.
We therefore used this dose to complete subsequent experiments.
Inflammatory markers were shown to be elevated at the perisurgical site
24 and 72 hours after SBI (Yamaguchi et al., 2007, Hyong et al., 2008). Resident
immune cells get activated due to the primary injury and release chemokines and
pro-inflammatory cytokines that induce endothelial cells to upregulate adhesion
molecules which promotes peripheral leukocyte trafficking to the injury site
(Hickey, 1999, Ransohoff et al., 2003). A number of studies show that
leukocytes accumulate in the CNS in response to an injury (Ransohoff et al.,
2003, Wang and Dore, 2007, Ma et al., 2014). Infiltrated immune cells and
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activated resident microglia release inflammatory mediators such as INF-γ and
IL-1β that increases tissue injury and potentiates neuroinflammation (Yilmaz et
al., 2006). Slit2 has been shown to have anti-migratory function including
inhibition of leukocyte migration (Wu et al., 2001, Tole et al., 2009, London et al.,
2010). We observed that recombinant Slit2 reduced expression of proinflammatory cytokines and peripheral immune cell markers at the perisurgical
site. These results suggest that recombinant Slit2 mediates protection at least in
part through reduction of neuroinflammation by decreasing brain infiltration of
peripheral immune cells.
To elucidate the anti-migratory mechanism of recombinant Slit2, we
explored the role of its receptor Robo1 (Guan and Rao, 2003) which we
observed was expressed by the peripheral immune cells. The second LRR
domain of Slit2 can directly bind with the first extracellular immunogloblulin (Ig)
domain of Robo1 (Wong et al., 2002, Guan and Rao, 2003, Ballard and Hinck,
2012). Robo1 knockdown neutralized the inhibitory effect of Slit2 for cellular
chemotaxis in vitro (Prasad et al., 2007, Mertsch et al., 2008). Altay et al.
previously showed that recombinant Robo1 acts as a decoy receptor by binding
to recombinant Slit2 which thereby makes less Slit2 available to bind to the
Robo1 receptors on immune cells to exert its anti-migratory function (Altay et al.,
2007). We therefore co-administered recombinant Robo1 along with recombinant
Slit2 as a decoy receptor to neutralize the effects of recombinant Slit2. Our
results complement the findings of Altay et al. and showed that recombinant
Robo1 reversed the protective effect of recombinant Slit2 by increasing brain
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infiltrated immune cell markers. This suggests that Slit2 regulates the migration
of peripheral immune cells to the brain dependent on Robo1.
Slit-Robo GTPase Activating Protein 1 (srGAP1) is a downstream effector
of Robo1 receptor (Wong et al., 2002). The SH3 domain of srGAP1 directly binds
to the intracellular CC3 motif of Robo1 receptor (Wong et al., 2001, Guan and
Rao, 2003). In the presence of Slit2, there is increased recruitment of srGAP1 to
Robo1 which induces the downstream signal transduction pathways. srGAP1
inactivates Cdc42, a small GTPase protein, by converting the active GTP-bound
form of Cdc42 to inactive GDP-bound form of Cdc42 (Wong et al., 2001, Yiin et
al., 2009). Cdc42 is a critical mediator for cell migration (Bishop and Hall, 2000,
Yiin et al., 2009). Activation of Cdc42 leads to filopodial extension at leading
edge of migrating cells which enables cells to move forward (Bishop and Hall,
2000, Kumar et al., 2012). Our results showed that srGAP1 siRNA reversed the
protective effects of recombinant Slit2 against SBI induced immune cell
infiltration. Additionally, we observed that Cdc42 activity was reduced by
recombinant Slit2 and this reduction was partially neutralized by recombinant
Robo1 co-administration and reversed by srGAP1 siRNA. This suggests that
Slit2 activation of the Robo1-srGAP1 pathway inhibits Cdc42 activity which
possibly reduced peripheral immune cell infiltration and neuroinflammation after
SBI.
In conclusion, our findings indicate that Slit2 contributes to protection
against neuroinflammation after SBI. Administration of recombinant Slit2 reduced
neuroinflammation after SBI by inhibiting peripheral immune cell infiltration
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possibly through Robo1-srGAP1 pathway mediated Cdc42 inactivation. These
observations suggest that Slit2 may be a potential therapeutic option to reduce
neurosurgical injury. Modulation of neuroinflammation by targeting peripheral
immune cell infiltration may be beneficial to improve post-operative outcomes in
neurosurgical patients.
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Abstract
Background and Purpose: Increase in blood brain barrier (BBB)
permeability following neurosurgical procedures can worsen post-operative brain
edema and neurological function. The extracellular matrix protein Slit2 has been
shown to have vascular anti-permeability effects outside the brain. This study
evaluated the effect of recombinant Slit2 and the role of its receptor roundabout4
(Robo4) and its downstream mediator paxillin in preserving the BBB integrity
after surgical brain injury (SBI) in a rat model.
Methods: Adult male Sprague-Dawley rats (280-350 g) were subjected to
sham or SBI surgery. Surgical brain injury was induced by partial resection of
right frontal lobe. Recombinant Slit2 was administered by intraperitoneal injection
1 h before SBI induction. Robo4 siRNA or paxillin siRNA was given by
intracerebroventricular injection 24 h before SBI. Evans blue dye extravasation,
neurological function, western blot for BBB junction proteins,
immunohistochemistry and Rac1 activity were evaluated 24 h after SBI.
Results: Recombinant Slit2 administration reduced Evans blue dye
extravsation and stabilized occludin expression after SBI. Robo4 and paxillin was
expressed by endothelial cells. The expression of paxillin was reduced after SBI
which was normalized with recombinant Slit2 administration. Recombinant Slit2
increased Rac1 activity which was reversed by Robo4 and paxillin siRNA.
Conclusions: Recombinant Slit2 reduced BBB permeability after SBI, possibly
by stabilizing the BBB tight junction through Robo4-paxillin mediated Rac1
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activation. These findings suggest that Slit2 may be beneficial to stabilize
neurosurgical injury to the BBB.

Keywords
Surgical brain injury, Blood brain barrier permeability, Slit2, Robo4, Paxillin,
Rac1.
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Introduction
Brain edema at the perisurgical site is a major pathophysiological
consequence following neurosurgical procedures (Bruder and Ravussin, 1999,
Bruder, 2002, Rolston et al., 2014). Post-operative edema has been reported to
occur in 2 to 10% cases after cranial tumor resection (Wong et al., 2012).
Increase in blood brain barrier (BBB) permeability contributes to perisurgical site
brain edema following neurosurgical injury in experimental surgical brain injury
(SBI) rodent model (Jadhav et al., 2007a, Yamaguchi et al., 2007). Disruption of
BBB tight junction and adherens junction proteins increases paracellular
permeability leading to the development of subsequent vasogenic edema which
can worsen patient neurological outcomes (Nag et al., 2011). Current treatment
regimes for post-operative brain edema do not target the specific BBB pathology
and have limited use due to unwanted adverse effects (Li et al., 2014, Xu et al.,
2014).
Slit2 is a secreted extracellular matrix protein known to regulate the
migration of axons and neurons during development (Marillat et al., 2002, Ballard
and Hinck, 2012). Recent studies show that Slit2 is increased in the brain
following traumatic and surgical brain injury (Hagino et al., 2003, Sherchan et al.,
2015), which implicates that Slit2 may have a role to play in the recovery after
brain injury in adults (Marillat et al., 2002). Additionally, previous studies have
demonstrated that Slti2 reduced endothelial hyperpermeability dependent on the
endothelial specific receptor Robo4. In a model of glioma cocultured endothelial
cells, Slit2 reduced blood tumor barrier (BTB) permeability which was inhibited
with knockdown of the endothelial specific receptor Robo4 (Cai et al., 2015).
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Likewise, recombinant Slit2 reduced vascular hyperpermeability in a Robo4
receptor dependent manner in mouse models of lung inflammation and
retinopathy (Jones et al., 2008, London et al., 2010). The endothelial stabilizing
effect of Robo4 has been shown to be mediated by the downstream effector
paxillin, an intracellular adaptor protein (Jones et al., 2009).
The role of Slit2 in regulating BBB permeability after brain injury including
SBI has not been explored. Based on these previous studies we propose that
recombinant Slit2 will activate Robo4-paxillin signal transduction pathway which
will attenuate BBB disruption after SBI in rats.

Materials and Methods
Animals
All procedures were approved by the Institutional Animal Care and Use
Committee at Loma Linda University following the NIH Guide for the Care and
Use of Laboratory Animals. Adult male Sprague Dawley rats (280-350 g) were
subjected to either SBI or sham surgery. Animals were housed in humidity and
temperature controlled environment with a 12 h light/dark cycle and free access
to food.

Experimental Design and Animal Groups
Experiment 1. The BBB protective effect of recombinant Slit2 was
evaluated. Rats were divided into 3 groups: Sham, SBI+Vehicle, SBI+Slit2 (10
µg/Kg). Recombinant Slit2 (R and D Systems, Minneapolis, MN, USA) or vehicle
normal saline was injected by intraperitoneal route 1 h before SBI. Neurological
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function was evaluated 24 h after surgery and brain samples from residual right
frontal lobe were collected for Evans blue dye extravasation assay and to
perform Western blot for BBB junction proteins.
Experiment 2. The expression and cellular localization of Robo4 and
paxillin after SBI was characterized. Rats were divided into 5 groups: Sham, SBI
6 h, SBI 12 h, SBI 24 h, and SBI 72 h. Brain samples from the residual right
frontal lobe were collected for immunohistochemistry and Western blot assay.
Experiment 3. The role of Robo4 and paxillin in recombinant Slit2
mediated protection was evaluated. Rats were divided into 6 groups: Sham,
SBI+Vehicle, SBI+Slit2 (10 µg/Kg), SBI+Slit2 (10 µg/Kg)+Robo4 siRNA,
SBI+Slit2 (10 µg/Kg)+Paxillin siRNA, SBI+Slit2 (10 µg/Kg)+Scramble siRNA.
Recombinant Slit2 or vehicle normal saline was injected intraperitoneally 1 h
before SBI. The siRNAs for Robo4, paxillin and scramble siRNA (all from Life
Technologies, Grand Island, NY, USA) was injected by intracerebroventricular
(ICV) route 24 h before SBI. Neurological function was evaluated at 24 h after
surgery and brain samples were collected for Western blot and Rac1 activity
assay.

Surgical Brain Injury Rat Model
Rats were subjected to surgical brain injury as previously described
(Jadhav et al., 2007b, Yamaguchi et al., 2007). Anesthesia was induced with 4%
isoflurane and maintained at 2.5% using a nasal mask. A midline skin was made
in the scalp and periosteum was reflected to expose the underlying frontal bone.
After identifying the bregma, a square craniotomy 5x5 mm was made on the right
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frontal bone with left lower corner towards bregma by using a micro drill. The
margins of the bone window were made 2 mm lateral to sagittal suture and 1 mm
proximal to coronal suture. The underlying dura was incised and a partial
resection of the right frontal lobe was performed along margins of the bone
window with the depth of resection extending to base of skull. Hemostasis was
achieved with normal saline irrigation and intraoperative packing following which
the skin incision was sutured. Sham animals were subjected to right frontal
craniotomy but without dural incision or frontal lobe resection. Buprenorphine
0.03 mg/Kg was injected subcuatenously for post-operative analgesia. Rats were
closely observed post-operatively for complete recovery from anesthesia and
then returned back to home cages.

Intracerebroventricular Injection
Rats were anesthetized with isoflurane and placed prone on a stereotactic
frame. Intracerebroventricular (ICV) injection into the right lateral ventricle was
performed by making a burr hole using the following coordinates relative to
bregma: 1.0 mm lateral, 1.5 mm posterior and 3.2 mm below the horizontal plane
of bregma as previously described (Suzuki et al., 2010, Chen et al., 2013). A 10
µL Hamilton syringe (Hamilton Co, Reno, NV, USA) was inserted through a burr
hole to inject the siRNAs. A total volume of 2 μL either Robo4 siRNA (500 pmol)
or paxillin siRNA (500 pmol) (Life Technologies, Grand Island, NY, USA) was
injected at a rate 0.5 μL/min as previously described (Suzuki et al., 2010, Chen et
al., 2013). The same volume of scramble siRNA (Life Technologies, Grand
Island, NY, USA) was injected as a negative control. The needle was left in situ
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for additional 10 mins after the completion of injection followed by slow
withdrawal over 5 mins to prevent leakage. The burr hole was sealed with bone
wax and skin incision was sutured. Rats were closely observed for complete
recovery from anesthesia and then returned back to home cages.

Neurological Evaluation
The modified Garcia test was performed to evaluate sensorimotor deficits
after SBI as previously described (Garcia et al., 1995, Ostrowski et al., 2005,
Yamaguchi et al., 2007). Briefly, the Garcia test evaluated six parameters that
included: spontaneous activity, symmetry in the movement of all four limbs,
forepaw outstretching, climbing, body proprioception, and response to vibrissae
touch. A total score of 21 was given, and higher scores indicated better
performance.

Evans Blue Dye Extravasation
Evans blue dye extravasation assay was performed to assess BBB
permeability as previously described (Jadhav et al., 2007a, Suzuki et al., 2010).
Briefly, Evans blue dye (2%; 5 mL/kg) was given by intraperitoneal injection and
allowed to circulate for 4 h after injection. The rats were transcardially perfused
with phosphate buffered saline (PBS) after which the brain samples were
removed and snap frozen in liquid nitrogen and stored at -80ºC until use. The
right frontal region was homogenized in PBS (1 mL/300 mg) and then centrifuged
at 14,0000 rpm for 30 mins after which the supernatant was collected. An equal
amount of trichloroacetic acid (50%) was added to 500 μL of the supernatant and
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allowed to incubate overnight at 4ºC. The supernatant was centrifuged using the
same parameters next day and quantity of extravasated Evans blue dye was
measured at 620 nm with a spectrophotometer.

Western Blot Analysis
Western blot was performed as previously described (Hasegawa et al.,
2011, Huang et al., 2015). Briefly, brain samples were collected after rats were
transcardially perfused with phosphate buffered saline (PBS) and then
homogenized in Ripa lysis buffer (Santa Cruz Biotechnology, Dallas, TX, USA)
for protein extraction. The supernatants from the samples were collected after
centrifuging at 14,000 g at 4oC for 30 mins, and protein concentration in the
samples was determined using a detergent compatibility assay (Biorad, Irvine,
CA, USA). Equal amounts of protein (50 µg) were loaded on to sodium dodecyl
sulfate polyacrylamide gel for electrophoresis and then transferred onto
nitrocellulose membranes. The membranes were then incubated overnight at
4oC with the following primary antibodies: anti-occludin (1:50,000) (Abcam,
Cambridge, MA, USA) and anti-VE cadherin (1:200), anti-Robo4 (1:200) and
anti-paxillin (1:500) (all from Santa Cruz Biotechnology, Dallas, TX, USA). The
same membranes were probed with anti-β Actin (1:2,000) (Santa Cruz
Biotechnology, Dallas, TX, USA) as loading controls. This was followed by
incubation of the membranes with appropriate secondary antibodies (1:4,000)
(Santa Cruz Biotechnology, Dallas, TX, USA) for 1 h at room temperature. The
bands were visualized using ECL Plus Chemiluminescence kit (Amersham
Biosciences, Arlington Heights, IL, USA) and quantified using Image J software
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(National Institutes of Health, Bethesda, MD, USA). Results were expressed as
relative density to β-actin and then normalized to average value of the sham
group as previously described (Hasegawa et al., 2011).

Immunohistochemistry
Briefly, after PBS perfusion and post-fixation in formalin, brain samples
were sectioned into 10-µm-thick slices using a cryostat (CM3050S; Leica
Microsystems, Bannockburn, IL, USA). Immunofluorescence staining was
performed as previously described (Hasegawa et al., 2011, Altay et al., 2012a).
The sections were incubated overnight at 4oC with the following primary
antibodies: anti-Robo4 (1:100) or anti-paxillin (1:100) (both from Santa Cruz
Biotechnology, Dallas, TX, USA) and co-localized with anti-von willibrand factor
(vWF) (1:100) (Santa Cruz Biotechnology, Dallas, TX, USA) or anti-glial fibrillary
acidic protein (GFAP) (1: 1,000) (Abcam, Cambridge, MA, USA). Sections were
then incubated with FITC- and Texas Red-conjugated appropriate secondary
antibodies (1:200) (Jackson Immuno Research, West Grove, PA, USA) for 2 h at
room temperature and visualized with a fluorescence microscope (Olympus
BX51).

Rac1 Activity Assay
A pulldown assay was performed using the Rac1 activity assay kit (Cell
Biolabs, San Diego, CA, USA) as previously described (Wojciak-Stothard and
Ridley, 2002, Raz et al., 2010). Briefly, samples were mixed with PAK1-PBD
agarose beads and incubated at 4°C for 1h after which the agarose beads were
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separated by centrifugation. The beads were then re-suspended in sample buffer
and then subjected to 10% polyacrylamide gel electrophoresis followed by
transfer to nitrocellulose membrane. The membrane was then probed with antiRac1 specific antibody provided in the kit to detect the GTP-bound Rac1.

Statistical Analysis
Statistical analysis was performed using the Sigma Plot 10.0 and Sigma
Stat version 3.5 (Systat Software, San Jose, CA, USA). Data were presented as
mean ± SEM. Statistical differences between groups were analyzed using oneway ANOVA for multiple comparisons followed by Student-Newman-Kuels or
Fisher L SD post hoc tests. P values less than 0.05 was considered statistically
significant.

Results
Recombinant Slit2 Administration Attenuated BBB
Permeability 24 Hours After SBI
The permeability of BBB was evaluated using Evans blue dye
extravasation assay at 24 h after SBI. Rats subjected to SBI had significantly
increased extravasated dye in the perisurgical right frontal region (p<0.05
compared to sham, Fig 1A). Recombinant Slit2 significantly reduced Evans blue
dye extravasation at the perisurgical site (p<0.05 compared to vehicle).
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Figure 1. Effect of recombinant Slit2 on BBB stability in the right frontal perisurgical
site 24 h after SBI. (A) Evans blue dye extravasation assay showed increased
leakage of the dye in perisurgical site after SBI which was significantly reduced
with recombinant Slit2 10 μg/Kg administration. (B) Representative Western blot
and quantitative analysis showed that the expression of occludin was significantly
decreased after SBI. Recombinant Slit2 10 μg/Kg significantly increased occludin
expression compared to vehicle group. (C) Representative Western blot and
quantitative analysis showed that the expression of VE cadherin did not change
after SBI. Data are expressed as mean ± SEM. *p<0.05 compared to sham,
†p<0.05 compared to vehicle.
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Recombinant Slit2 Preserved Tight Junction Protein
Expression 24 Hours After SBI
The BBB junction proteins occludin and VE cadherin in the right frontal
region was evaluated using Western blot analysis 24 h after SBI. The expression
of occludin was significantly reduced in the perisurgical site 24 h after SBI
(p<0.05 compared to sham, Fig. 1B), and recombinant Slit2 significantly
increased occludin expression (p<0.05 compared to vehicle). However, the
expression of VE cadherin was not significantly different between sham or SBI
groups at 24 h (p>0.05, Fig. 1C).

Cellular Localization of Robo4 After SBI
Immunofluorescence staining of brain samples was performed to delineate
the cell types that express Robo4 receptor 24 h after SBI. Double
immunofluorescence staining showed that Robo4 was expressed by endothelial
cells and neurons but not astrocytes in the perisurgical site after SBI (Fig. 2).
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Figure 2. Localization of Robo4 in the brain after SBI. Representative
microphotographs of immunofluorescence staining showed co-localization of
Robo4 (FITC/green) with endothelial marker von Willibrand Factor (vWF) (Texas
Red/red) and DAPI in the perisurgical site at 24 h after SBI. The lower panel shows
that Robo4 (FITC/green) was expressed by neurons but did not co-localize with
the astrocyte marker glial fibrillary acidic protein (GFAP) in the perisurgical site.
Scale bar=50 μm.
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Temporal Expression and Cellular Localization of Paxillin
After SBI
The temporal expression of paxillin in the perisurgical site was measured
using Western blot analysis at 6h, 12h, 24h and 72h after SBI. The expression of
paxillin was not significantly different from sham at 6h, 12h and 24h after SBI
(p>0.05 compared to sham, Fig. 3A). However, the expression of paxillin started
to decrease at 24 h after SBI and was significantly reduced at 72 h after SBI
(p<0.05 compared to sham). Double immunofluorescence staining showed that
paxillin co-localized with endothelial cells and astrocytes at the persurgical site
24 h after SBI (Fig. 3B).

95

Figure 3. Temporal expression and localization of paxillin in the brain after SBI.
(A) Representative Western blot and quantitative analysis showed that the
expression of paxillin started to decrease 24 h after SBI and showed a significant
decline at 72 h after SBI. Data are expressed as mean ± SEM. *p<0.05 compared
to Sham, &p<0.05 compared to SBI at 6 h, ‡p<0.05 compared to SBI at 12 h. (B)
Representative microphotographs of immunofluorescence staining showing colocalization of paxillin (FITC/green) with endothelial marker von Willibrand Factor
(vWF) or astrocyte marker glial fibrillary acidic protein (GFAP) (Texas Red/red) and
DAPI in the perisurgical site at 24 h after SBI. Scale bar=50 μm.
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Recombinant Slit2 Increased Rac1 Activity After SBI
Dependent on Robo4-Paxillin Pathway
The assay for Rac1 activity was performed at 24 h after SBI. Recombinant
Slit2 significantly increased Rac1 activity (p<0.05 compared to vehicle, Fig. 4A)
which was reversed with administration of Robo4 siRNA (p<0.05 compared to
Slit2) or paxillin siRNA (p<0.05 compared to Slit2) but not with scramble siRNA
(p>0.05 compared to Slit2). In addition, paxillin siRNA significantly worsened
neurological function compared to Slit2 10 µg/Kg or scramble siRNA which was
evaluated using Garcia test 24h after SBI (p<0.05 compared to Slit2 and
scramble siRNA, Fig. 4B) whereas, Robo4 siRNA partially worsened neurological
function compared to Slit2. Robo4 siRNA but not scramble siRNA effectively
suppressed the expression of Robo4 (p<0.05 compared to Slit2 and scramble
siRNA, Fig. 4C). Likewise, paxillin siRNA but not scramble siRNA significantly
suppressed the expression of paxillin (p<0.05 compared to Slit2 and scramble
siRNA, Fig. 4D).
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Figure 4. Role of Robo4-paxillin in Slit2 mediated protection after SBI. (A) Rac1
activity assay showed that recombinant Slit2 10 μg/Kg significantly increased Rac1
activity in the right frontal perisurgical site at 24 h after SBI. Robo4 siRNA and
Paxillin siRNA reversed this effect but not scramble siRNA. (B) Garcia test showed
significantly worse neurological function after SBI. Paxillin siRNA administration
along with Slit2 10 µg/Kg significantly worsened neurological function compared to
Slit2 10 µg/Kg or scramble siRNA. (C) Representative Western blot image and
quantitative analysis showed that the expression of Robo4 was significantly
reduced with Robo4 siRNA administration but not with paxillin or scramble siRNA.
(D) Representative Western blot image and quantitative analysis showed that
paxillin siRNA but not scramble siRNA significantly reduced paxillin expression
compared to Slit2 10 µg/Kg. Data are expressed as mean ± SEM. *p<0.05
compared to Sham, †p<0.05 compared to SBI+Vehicle, @p<0.05 compared to
SBI+Slit2 10 μg/Kg, #p<0.05 compared to SBI+Slit2+Robo4 siRNA, $p<0.05
compared to SBI+Slit2+paxillin siRNA.
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Discussion
This study examined the BBB protective effects of recombinant Slit2
administration in a rat SBI model. Recombinant Slit2 reduced BBB permeability
which was associated with preservation of the endothelial tight junction protein.
The BBB protective effects of recombinant Slit2 was possibly mediated by
stabilization of tight junction through Robo4-paxillin dependent activation of Rac1
after SBI.
Although primarily involved in regulating the migration of developing axons
and neurons (Marillat et al., 2002), recent studies have demonstrated that Slit2
can exert its effects on other cells types including endothelial cells and is
involved in regulating vascular integrity (Cai et al., 2015). Slit2 was shown to
inhibit VEGF-induced endothelial hyperpermeability in vitro and in mouse models
of retinal and choroidal vascular disease (Jones et al., 2008). In accordance with
previous studies, we observed that recombinant Slit2 administration reduced
extravasation of the albumin-bound Evans blue dye into the perisurgical site after
SBI suggesting that Slit2 reduced BBB permeability possibly by preserving the
endothelial junction integrity.
The BBB integrity is maintained by interendothelial tight junction and
adherens junction proteins (Nag et al., 2009). Tight junction proteins such as
occludin and claudin-5 maintain barrier function of the BBB, and disruption of
tight junction proteins enhances the endothelial barrier permeability after injury to
the brain (Altay et al., 2012b). Various factors such as inflammation, oxidative
stress and proteases can degrade tight junction proteins after brain injury (Altay
et al., 2012b, Krafft et al., 2013). Previous studies show that tight junction
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proteins were degraded in the perisurgical site following SBI thereby increasing
BBB permeability and brain edema (Yamaguchi et al., 2007). The endothelial
protective function of Slit2 has been shown to be associated with stabilization of
inter-endothelial junctions in vitro (Gorbunova et al., 2013). In accordance, we
observed that recombinant Slit2 administration increased the expression of
occludin suggesting that Slit2 regulates the expression of endothelial tight
junction proteins after SBI. However, we did not observe any change in the
expression of adherens junction protein VE cadherin after SBI with or without
Slit2 administration. Furthermore, Slit2 inhibited VEGF induced retinal
permeability in Robo4+/+ mice but not in Robo4 null mice suggesting that Slit2dependent inhibition of VEGF induced permeability was mediated via Robo4
activation (Jones et al., 2008). We therefore investigated the role of Robo4 in
Slit2 mediated stabilization of BBB after SBI.
Among the Robo family receptors, Robo4 is known to be the endothelial
specific receptor for Slit2 ligand (Huminiecki et al., 2002, Ballard and Hinck,
2012). Robo4 receptor has been demonstrated to be expressed by human brain
microvascular endothelial cells (Cai et al., 2015). Consistent with these findings,
we observed that Robo4 was expressed by endothelial cells at the perisurgical
site in SBI rats. Furthermore, previous study showed that transgenic
overexpression of Robo4 by glioma cocultured endothelial cells reduced BTB
permeability by preserving tight junction protein expression in vitro (Cai et al.,
2015). We speculate that recombinant Slit2 binds to Robo4 receptors on the
endothelial cells and regulates the expression of tight junction proteins.
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Interestingly, we also found that Robo4 was expressed by neurons but not
astrocytes surrounding the perisurgical site. However, the regulation of Robo4
expression after SBI remains to be further explored.
Next, we investigated the role Robo4 and its downstream mediator paxillin
in Slit2 mediated BBB stabilization by Rac1 activation. Paxillin is a critical
downstream effector of Robo4 in endothelial cells (Jones et al., 2009). The
Paxillin Interaction Motif (PIM) in the cytoplasmic tail of Robo4 directly interacts
with Lim domain of paxillin (Jones et al., 2009). Binding of Slit2 ligand to Robo4
increases the interaction of Robo4 with paxillin and Arf-GAP complex (Jones et
al., 2009). The Arf-GAP complex inactivates Arf6 which is a small GTPase
protein that induces the internalization of Rac1 (Palacios et al., 2001, Turner et
al., 2001). However, in the presence of Slit2, the interaction between Robo4paxillin increases and Arf6 gets inactivated thereby restoring Rac1 activity. The
small GTPse Rac1 is an important mediator known to stabilize adherens junction
and tight junction complexes that maintain endothelial barrier integrity (WojciakStothard and Ridley, 2002, Waschke et al., 2004). We observed that recombinant
Slit2 administration increased Rac1 activity after SBI which was reversed with
siRNA mediated knockdown of either Robo4 or paxillin. Based on these findings,
we propose that Slit2 preserved BBB integrity after SBI possibly by Robo4paxillin mediated activation of Rac1 which stabilized the tight junction. We
observed that paxillin was expressed by endothelial cells and astrocytes
surrounding the perisurgical site. Interestingly, we also observed that the
expression of paxillin decreased following SBI and was normalized with
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recombinant Slit2 administration. Previous study showed that paxillin was
localized at the focal adhesions in the cell periphery and Slit2 exposure
redistributed paxillin from focal adhesions to the cell surface (Jones et al., 2009).
It is likely that recombinant Slit2 redistributed paxillin to the cell surface and
restored its expression after SBI-induced injury. However, in depth evaluation of
the regulation of paxillin after SBI and with Slit2 remains to be studied.
In conclusion, our findings suggest that recombinant Slit2 reduced BBB
permeability by stabilizing endothelial tight junction after experimental SBI
possibly via Robo4-paxillin dependent Rac1 activation.
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CHAPTER 5
DISCUSSION AND CONCLUSION

Summary of Findings
This project examined the potential role of the extracellular matrix protein,
Slit2 and its receptor Roundabout (Robo) in reducing complications following
neurosurgical injury. We specifically examined the contribution of Slit2 in
reducing neuroinflammation and blood brain barrier (BBB) disruption after
surgical brain injury (SBI) using a rat model. The major observations and
conclusions obtained from the project have been summarized in this section.

Endogenous Slit2 has a Protective Function After SBI
Our findings from Chapter 3 show that endogenous Slit2 has a protective
function after SBI. We observed that endogenous Slit2 was upregulated after SBI
starting at 24 h upto 7 days after the injury, and knockdown of endogenous Slit2
using siRNA worsened brain edema and neurological function after SBI. In
addition, we observed that Slit2 was expressed by neurons and astrocytes after
the injury, which we speculate is the source for increase in endogenous levels of
Slit2 as a protective response to injury. These findings complement previous
study in which Slit2 was shown to be increased after traumatic brain injury
(Hagino et al., 2003). Although the function of endogenous Slit2 in adults after
brain injury has not been explored, our findings that endogenous Slit2
knockdown worsened outcomes after SBI suggests a protective role of Slit2
following brain injury.
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Recombinant Slit2 Reduces SBI Induced Complications
Our findings from Chapter 3 show that recombinant Slit2 pretreatment
reduced SBI induced brain edema and neurological deficits in SBI rats. The
improved outcomes with recombinant Slit2 pretreatment was associated with
reduced neuroinflammation and peripheral leukocyte migration to the perisurgical
site after SBI. Post-operative brain edema is one of the major complications
encountered in neurosurgical patients (Wong et al., 2012). Neuroinflammation
and disruption of the BBB can worsen brain edema and post-operative
neurological function (Bruder and Ravussin, 1999, Hyong et al., 2008, Huang et
al., 2015), which were both attenuated with recombinant Slit2. Additionally, our
results from Chapter 4 show that recombinant Slit2 reduced BBB permeability
and stabilized the BBB tight junction at the perisurgical site after SBI. These
findings support the therapeutic potential of recombinant Slit2 to reduce
neuroinflammation and BBB disruption following brain injury.

Robo Receptor Mediated Signaling Pathways Contribute to
the Protective Effects of Slit2
The Robo family of receptors is known to be activated by the Slit2 ligand
(Guan and Rao, 2003, Ballard and Hinck, 2012). We evaluated the role of Robo1
and Robo4 receptors in Slit2 mediated protection after SBI. Our findings in
Chapter 3 show that Robo1 was expressed by peripheral immune cells that
infiltrated at the perisurgical site after SBI. Our results suggest that inactivation of
Cdc42 via Robo1-srGPA1 pathway contributed to the inhibition of peripheral
immune cell migration by recombinant Slit2. Knockdown of Robo1 or srGAP1
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reversed the anti-migratory effect of recombinant Slit2 on the peripheral immune
cells. Likewise, our findings in Chapter 4 show that Robo4 was expressed by the
endothelial cells. The BBB protective function of recombinant Slit2 was
associated with Robo4-paxillin mediated Rac1 activation, and knockdown of
Robo4 or paxillin reversed Slit2 mediated Rac1 activation. These findings
suggest that Robo1 and Robo4 receptors are primarily involved in mediating the
protective effects of Slit2 by modulating the downstream signaling pathways.

Scientific Contribution
This project was focused on studying SBI, which is an important clinical
problem that has largely been overlooked due to a lack of understanding of the
occurrence of the problem. Even though adverse events such as brain edema
and post-operative neurological deficits often occur following neurosurgical
procedure (Bruder and Ravussin, 1999, Rolston et al., 2014), the
pathophysiology of SBI is often not studied. This project explored two major
pathophysiological events that occur after SBI. First, the role of peripheral
immune cell migration in mediating neuroinflammation after SBI was examined
particularly with a focus on Robo1 mediated immune cell migration to the injury
site. Second, post-operative brain edema resulting from BBB junction disruption
was examined with a focus on restoring BBB stability after SBI.
This project has identified novel molecular mechanisms involved in Slit2
mediated neuroprotection. Slit2 has primarily been studied in the developing
nervous system and few studies have explored the role of Slit2 in adult brain
(Marillat et al., 2002, Mertsch et al., 2008). Even thought previous studies have
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shown that Slit2 reduced injury outside the CNS in animal models of renal and
lung inflammation (Kanellis et al., 2004, Ye et al., 2010), the function of Slit2 after
brain injury has been relatively unexplored. Slit2 was shown to be increased after
experimental traumatic brain injury (Hagino et al., 2003) and exogenous Slit2
was beneficial in a cerebral ischemia rodent model (Altay et al., 2007). However,
functional significance of Slit2 after brain injury and the protective mechanism of
Slit2 were not determined. Our findings in this project provide evidence that Slit2
has a protective role after brain injury. We have elucidated previously unknown
dual function of Slit2 after brain injury, which includes reducing
neuroinflammation by inhibiting the migration of peripheral immune cells and antipermeability effects by stabilizing the BBB tight junction. Furthermore, our
findings demonstrate that the protective mechanism of Slit2 is mediated via
Robo1 receptor expressed by peripheral immune cells and Robo4 receptor
expressed by BBB endothelial cells. These novel findings show that exogenous
Slit2 administration targets two major pathophysiological events after SBI and
thereby augments the body’s endogenous protective response against SBI.
Overall, these findings provide evidence that Slit2 has beneficial role after
SBI and is a potentially suitable therapeutic candidate to reduce deleterious
consequences after SBI and possibly other brain injuries with similar pathologies.

Limitations and Future Directions
The major limitations in this project are discussed in this section.
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Role of Other Members of the Slit Protein Remains to be
Elucidated
This project primarily focused on exploring the role of Slit2 after SBI even
though there are three known isoforms of Slit proteins (Slit1-Slit3) (Guan and
Rao, 2003, Hohenester, 2008). Studies show that other Slit members may
regulate processes in the CNS too. For instance, Slit1 is predominantly
expressed in the developing CNS and Slit3 has been reported to have antipermeability effects following VEGF induced retinal hyperpermeability (Marillat et
al., 2002, Jones et al., 2008). Given these findings, it is likely that Slit1 and Slit3
may be involved during recovery after CNS injury. However, Hagino et al.
observed that Slit2 was predominantly expressed surrounding the lesion after
traumatic brain injury in mice while the expression of Slit1 and Slit3 was much
weaker (Hagino et al., 2003). In accordance, we observed that the expression of
Slit2 was increased after SBI. However, we did not evaluate if Slit1 and Slit3
exhibit any changes after SBI. Neither did we explore therapeutic potential of the
other Slit members after SBI. A detailed examination of all members of the Slit
family after brain injury is warranted.

Alternate Pathways in Slit2 Mediated Protection Need to be
Evaluated
This project examined two primary pathways in Slit2 mediated protection
after SBI which included the Robo1-srGAP1 pathway regulating
neuroinflammation and the Robo4-paxillin pathway maintaining the endothelial
barrier stability by recombinant Slit2. However, Slit2 can activate alternate
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pathways, which was not explored in this project.
For instance, (1) Downstream effectors such as Abelson kinase (Abl) and
Enabled (Ena) can interact with the intracellular motif of Robo and regulate cell
migration. Abl antagonizes the repulsive effects of Robo whereas, Ena enhances
Robo mediated repulsive signaling pathway (Ballard and Hinck, 2012). (2) We
measured Cdc42 activity as the downstream substrate of srGAP1 but other small
GTPases including RhoA and Rac1 that regulate cellular actin organization and
motility were not evaluated in this project (Wojciak-Stothard and Ridley, 2002,
Waschke et al., 2004). (3) Previous studies have shown that Slit2 can inhibit
chemokine induced Src kinase activity and Lck kinase activity which have been
reported to regulate cell migration (Prasad et al., 2007). (4) The endothelial
barrier protective effect of Slit2 may be mediated by modulation of
matrixmetalloproteinase (MMP)-9 activity which was not explored (Cai et al.,
2015). (5) Lastly, using knockout or transgenic animals would strengthen the
findings in our project. It was previously observed that Robo4 null mice had
increased severity of lung injury than Robo4+/+ mice when subjected to lung
inflammation (London et al., 2010), which proposes a protective function for Slit2Robo4. However, Slit2 transgenic mice were more susceptible to collagenase
induced ICH and had larger hemorrhagic volumes compared to control mice
(Han and Geng, 2011). The findings in this study conflict with the protective
effects of Slit2 observed in other animal models of CNS injury (Altay et al., 2007,
Sherchan et al., 2015). This suggests that endogenous Slit2 overexpression and
exogenous Slit2 possibly have diverse functions and mechanisms on the
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endothelial cells.
Additionally, the findings in these studies could be attributed to differences
in the animal model used, differential mechanism of the endogenous versus
exogenous Slit2, or due to differences in the magnitude of exposure to Slit2 in
transgenic animals as opposed to exogenous recombinant Slit2 administration.
Although the temporal pattern and duration of Slit2 expression in transgenic
animals subjected to injury and the mechanism of injury was not explored, these
findings necessitate further exploration of the function of Slit2 after brain injury.

Detailed Exploration of the Robo Receptor Subtypes is
Required
The effect of Slit2 may depend on the type of receptor predominantly
expressed following an injury. Furthermore, the expression and function of Robo
receptors may be tissue specific and context dependent. For instance, Slit2
reduced permeability in human pulmonary microvascular endothelial cells
(PMECs) that predominantly express Robo4 (Gorbunova et al., 2013), but the
anti-permeability effect of Slit2 was not observed in the human umbilical vein
endothelial cells (HUVECs) which express similar levels of Robo4 and Robo1
receptors (Gorbunova et al., 2013). Therefore, an in depth understanding of the
expression of Robo receptors and changes that may occur after SBI is required.

Upstream Regulators of Slit2 Need to be Explored
The transcription factor such as Pax6 has been shown to regulate the
expression of Slit2 (Tsuchiya et al., 2009). Additionally, changes in SLIT2 gene,
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for instance hypermethylation of the gene in systemic tumors and glioma have
been observed (Dallol et al., 2003). Our findings showed that endogenous Slit2
levels increased after SBI as a protective response to counteract the
consequences of SBI. However, the upstream regulators for Slit2 were not
examined. Further exploration into the regulation of endogenous Slit2 is essential
to understanding this response.

Conclusion
Our findings suggest that Slit2 has a beneficial role against
neuropathological consequences after SBI. The protective effect of Slit2 against
SBI was possibly mediated by its anti-migratory function against peripheral
leukocytes and by endothelial barrier stabilization dependent on the Robo
receptors. The dual protective function of Slit2 makes it a potential therapeutic
option to reduce neurosurgical injury and improve post-operative outcomes in
neurosurgical patients.
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